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In the Netherlands, about 350 new patients per year are diagnosed with a
malignant testicular germ cell tumor.1 This corresponds with an annual incidence
of about 3 per 100.000. Germ cell tumors are the most prevalent type of
malignancy in men aged between 20 and 35 years. Two to three per cent of the
patients have bilateral tumors.2 Bilateral tumors usually occur metachronally, and
only very rarely synchronously.3 Malignant germ cell tumors occasionally run in
families, but it is not clear whether heredity plays a role.4
Etiology
The only proven risk factor for the development of a testicular tumor is
cryptorchidism. Twelve per cent of the testicular tumors arise in patients with an
undescended testicle. The risk that a tumor will develop in an undescended
testicle is 20 to 40 times higher than in a testicle that descends normally.5,6 There
is also a higher incidence of testicular tumors in men infected with the human
immunodeficiency virus (HIV).7,8 In addition, the presence of testicular atrophy
may influence the development of testicular tumors. It has also been found that
the Klinefelter syndrome is associated with mediastinal germ cell tumors and that
orchitis forms a possible risk factor.9
Dissemination
In principal, the dissemination route of testicular germ cell tumors is no different
from that of other malignant tumors. Tumor cells can spread via the lymphatic
and circulatory systems. The first lymph node stations of the testes are the lumbar
lymph nodes, which are located close to the vertebral column at the level of L2 to
L4. From there, tumor cells can spread lymphogenously, via the thoracic duct to
the mediastinum and supraclavicular lymph nodes. Haematogenic dissemination
can take place in two ways: directly to the lungs via vascular invasion in the
testicle, or indirectly to the lungs via the lumbar lymph nodes, cisterna chyli and
the thoracic duct to the subclavian vein. Direct invasion of
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adjacent structures, such as the rete testis, epididymis and the spermatic cord, can
also occur. However, malignant germ cell tumors chiefly disseminate via the
lymphogenous route.10
Symptomatology
A testicular tumor usually presents as a painless swelling in the testicle. Slight
trauma often draws a patient’s attention to the swelling. Other possible symptoms
resemble orchitis, epididymitis or testicular torsion. Some patients present without
any testicular complaints or abnormalities, but with symptoms of distant
metastases. Retroperitoneal lymph node metastases can cause back pain or renal
colic by compressing or blocking the ureter. Lung metastases can give rise to
dyspnoea, haemoptysis and pleural irritation. In addition, gynaecomastia can form
the first clinical symptom of a tumor that is producing human chorionic
gonadotrophin (hCG).11
Diagnosis and staging
Differential diagnoses in the case of testicular complaints comprise a malignancy,
varicocele, hydrocele, spermatocele, epididymitis, orchitis, testicular torsion and
lateral inguinal hernia. It is important to establish whether the scrotal swelling is
intratesticular or extratesticular. Intratesticular swellings should be considered
malignant until proven otherwise, whereas extratesticular swellings are generally
benign. Physical examination includes thorough palpation of the scrotal contents,
palpation of the abdomen, supraclavicular lymph nodes and the mammae in case
gynaecomastia is present. Ultrasonography of the scrotal contents is the
examination of choice to distinguish between an intratesticular and an extra-
testicular swelling. Laboratory investigations play varying roles. In patients with a
seminoma, the serum hCG may be slightly increased and there is usually a higher
than normal level of placenta-like alkaline phosphatase (PLAP). In patients with
nonseminomatous germ cell tumors, specific serum tumor markers may be
present, namely hCG and alpha-fetoprotein (AFP). In all patients with a malignant
germ cell tumor, the serum lactate dehydrogenase (LDH) level may be increased.
Diagnosis is made on the basis of histological examination of tissue obtained after
orchidectomy via an inguinal incision. Orchidectomy is performed if the
13
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testicular swelling is clinically suspicious and the laboratory results are abnormal.
If the swelling is clinically suspicious, but the laboratory results are normal, the
first step is to perform explorative surgery and take biopsies. The frozen section
histology technique is used to establish whether or not the swelling is malignant.
If the abnormality appears to be benign, the testicle is generally replaced in the
scrotum, whereas if it is malignant, orchidectomy is performed.
A patient in whom a germ cell tumor has been diagnosed must undergo further
staging examinations. Besides physical examination and laboratory tests, these
comprise computed tomography (CT scans) of the abdomen and chest. There are
no indications to perform Magnetic Resonance Imaging (MRI).12 At the
University Hospital Groningen, the staging classification according to Peckham is
used (Table 1).13
Table 1. Staging for testicular tumors according to Peckham
Stage I Tumor limited to the testis
Stage II Infradiaphragmatic lymph node involvement
IIA metastases <2 cm in diameter
IIB metastases 2-5 cm in diameter
IIC metastases >5 cm in diameter
Stage III Supra- and infradiaphragmatic lymph node involvement;
Abdominal status A, B, C as for Stage II;
No extralymphatic metastases
Stage IV Extra lymphatic metastases; Abdominal status A, B, C
as for Stage II; 0 for negative nodes; Lung status:
L1 ≤3 metastases; ≤2 cm in diameter
L2 multiple metastases; ≤2 cm in diameter






Testicular germ cell tumors can be divided into seminomas (± 55%) and
nonseminomas (± 45%). Nonseminomas can be further divided into a number of
subgroups. Various classifications have been developed over the years. At the
University Hospital Groningen, the classification of the World Health
Organisation (WHO) is used (Table 2).14
Table 2. Histological classification of testicular tumors,
World Health Organisation










c. With malignant transformation
B. Tumors of more than one histological type
1. Embryonal carcinoma and teratoma (teratocarcinoma)
2. Choriocarcinoma and any other types
3. Other combinations
A nonseminoma can consist of one component, but there is usually a combination
of components, whether or not including seminoma. Embryonal carcinoma is the
most poorly differentiated tumor component; no specific differentiation direction
is recognisable. Yolk sac tumor and choriocarcinoma resemble fetal membranes
and placental tissue, respectively. Teratoma can contain a mixture of tissues, such
as epithelium, cartilage, muscle or nerve tissue. When these tissues have a more
or less normal structure, with good recognition of the differentiation
15
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direction, the tumor is referred to as mature teratoma. When these tissues are not
fully evolved, the tumor is referred to as immature teratoma. As testicular tumors
often contain different components, it is very important to examine various areas
of the tumor histologically. Staging of the primary tumor is performed according
to the guidelines of the Union Internationale Contre le Cancer (UICC). In Table 3
clinical-macroscopic staging and histological staging are described.15
Table 3. Tumor staging according to the UICC
Macroscopic Histological
staging staging
T0 no primary tumor pT0
T1 limited to the body of testis pT1
T2 invading beyond the tunica albuginea pT2
T3 invading rete testis or epididymis pT3
T4 infiltrating spermatic cord and/or pT4
scrotal wall
T4a infiltrating spermatic cord pT4a
T4b infiltrating scrotal wall pT4b
TX minimum requirements to assess stage pTX
can not be met
16
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I.2 TREATMENT AND FOLLOW-UP
Historical developments
The role of surgery in the treatment of patients with testicular tumors has changed
considerably over the years. Until the end of the previous century, treatment for
these patients comprised orchidectomy alone.16,17 However, physicians had been
aware for some time that patients might have metastases in the retroperitoneum.
In 1887, Kocher was the first to describe the resection of a retroperitoneal mass
from a patient with a testicular tumor.18 He removed a tumor mass that was ’as
large as a man’s head’ from the retroperitoneum. However, the patient developed
local recurrence five months later. The first transabdominal retroperitoneal lymph
node dissection was performed by Roberts in 1902; however, the patient died of
peritonitis.19 Lumbar retroperitoneal lymph node dissection was described for the
first time by Chevassu20 and Howard21 in 1910. Coley was opposed to performing
retroperitoneal lymph node dissection, because at that time (1915) the surgical
mortality rate was 10% to 15%, which he considered too high to be acceptable.
An additional argument was that in 50% of the patients with testicular tumors, no
tumor-bearing lymphatic tissue was found during surgery. Coley therefore injected
patients who had a malignant testicular tumor with ’Coley’s fluid’.17 The fluid
comprised a mixture of Bacillus prodigiosus toxin and a filtrate of haemolytic
streptococcus. The encouraging results of this therapy were very likely due to
hyperthermia caused by the toxins.22 In this period, radiotherapy was also applied
for the first time. In 1916, Béclère was probably the first to use radium on a
retroperitoneal metastasis from a testicular tumor.23 Orbaan, a Dutch physician,
was the first to publish the results of treating metastases from ovarian and
testicular tumors with radiotherapy.24
In 1923, Hinman described the results of patients with a testicular tumor who he
had treated with a so-called ’radical operation’, by this he meant retroperitoneal
lymph node dissection (RPLND).25 He concluded that his results signified an
improvement of 100% in comparison with treatment comprising orchidectomy
alone. At that time, orchidectomy alone cured only 15% of the patients, while the
’radical operation’ was said to have cured 30%. Until the end of the 1930s,
RPLND was the standard treatment after orchidectomy, irrespective of whether a
patient had a seminoma or a nonseminomatous tumor. In the subsequent period,
physicians somewhat lost interest in RPLND because of the good results of
17
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radiotherapy, particularly in patients with a seminoma.26 It was not until 1948 that
Lewis propagated treating seminomas differently from nonseminomas.27 He
concluded that patients with a seminoma should be treated with orchidectomy and
radiotherapy, while patients with a nonseminomatous testicular tumor should be
treated with orchidectomy, RPLND and radiotherapy.
A little later, the discussion in the literature became chiefly focused on the
surgical approach to RPLND. Cooper et al. introduced a thoraco-abdominal
approach to ipsilateral RPLND.28 Variations of the technique were then described
by Vallet29 and Lewis.30 In 1953, Leadbetter published his results, on the basis of
which he concluded that besides ipsilateral lymph node dissection, contralateral
lymph node dissection should also be performed.31 Following the work of Roberts
in 1902,19 Mallis et al.32 and Stehlin et al.33 described a transabdominal approach
to bilateral retroperitoneal lymph node dissection in 1958 and 1959, respectively.
Recent developments
At the University Hospital Groningen, bilateral RPLNDs were introduced in 1963.
The transabdominal approach was used and dissection was limited to the
retroperitoneal lymph nodes caudal to the renal vessels. In patients with
nonseminomatous testicular germ cell tumors (NSTGCT), Wobbes described the
results of treatment over the period 1963 to 1977.10 During that period,
retroperitoneal lymph node dissection was considered to be the standard
diagnostic and therapeutic intervention in patients with clinical stage I NSTGCT.
Metastases were found in the retroperitoneal lymph nodes in 25% to 35% of the
patients. The majority of these patients were subsequently treated with
actinomycin-D chemotherapy, because of its cytostatic effect.34 If, during surgery,
it was found that RPLND was not possible because the metastases were too
extensive, the patient received actinomycin-D and a second attempt was made at a
later date. In patients with distant metastases, chemotherapy has been playing a
major role since the beginning of the 1950s. At first, treatment usually comprised
a single drug, sometimes in combination with actinomycin-D. In 1960, Li
described the results obtained with a combination of chlorambucil, methotrexate
and actinomycin-D.35 The advantage of combination therapy is the synergistic
effect, because different drugs are active against different parts of the cellular
process. In addition, a nonseminomatous tumor can contain one or more
components, with different levels of chemo-sensitivity.
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At the beginning of the 1970s, the first results were described of treatment with
vinblastine and bleomycin.36-38 Response rates varied from 32% with
monotherapy, to 90% with combination therapy. The first real breakthrough in the
treatment of patients with disseminated NSTGCT occurred in 1977. In that year
the results were published of treatment with cisplatin in combination with
vinblastine and bleomycin (PVB).39 This combination appeared to be so effective
that it was decided to change the treatment policy of these patients into PVB
followed by the possible resection of residual retroperitoneal and/or pulmonary
metastases. PVB polychemotherapy was introduced at the University Hospital
Groningen in 1977.40 The combination was applied as the standard treatment for
many years. In view of the high level of toxicity, various modifications were
investigated, which led to a new standard: the combination of bleomycin,
etoposide and cisplatin (BEP).41
In the 1970s, CT scanning was introduced which enabled more accurate clinical
staging than had been possible previously with lymphangiography and lung
tomography.42,43 In the early stages, CT scanning of the retroperitoneal region was
not considered to be totally reliable. Therefore, explorative laparotomy was
performed to be completely certain about the presence or absence of retro-
peritoneal lymph node metastases. However, it soon became apparent that
explorative laparotomy did not have any consequences on the clinical stage
established on the basis of the CT findings. During an interim analysis it was
decided to perform laparotomy only in cases in whom CT scanning could not
give a definite answer about retroperitoneal lymph node metastases. The role of
MRI in determining the effect of the treatment for patients with disseminated
NSTGCT was also examined. Hogeboom found that MRI did not have any
advantages over CT scanning.44 Since then, newer MRI equipment has become
available (with breath holding techniques), so the value of MRI compared to CT
scanning of the retroperitoneum will have to be re-evaluated.
Another important development in relation with diagnosis and staging is the
possibility of measuring tumor marker levels (hCG and AFP) in a patient’s serum.
The response to treatment can be monitored by means of hCG and AFP, but it is
important to measure the serum levels of these markers prior to orchidectomy to
record the original levels.45,46 Owing to the fact that at least 20% of NSTGCT do
not produce tumor markers, attempts have been made to find new tumor markers
over the past few years. In 1991, a serum immuno-enzymometric assay was
developed at the Immunochemistry Laboratory of the
19
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University Hospital Groningen for the detection of TRA-1-60 reactive antigen.47
This antigen is found in patients whose primary tumor contains embryonal
carcinoma. TRA-1-60 is a very promising potential tumor marker, because
embryonal carcinoma is the most common histological component of NSTGCT.
In patients with clinical stage I NSTGCT, the cure rate after RPLND was about
80% to 90%.48 However, nearly all of the patients developed retrograde
ejaculation, because the sympathetic ganglia and the hypogastric plexus had been
damaged. As this group of patients chiefly comprises young men, this is a very
serious complication.49,50 In addition, in 65% to 75% of the cases, RPLND only
had diagnostic value, without any therapeutic consequences, because no metastatic
viable cancer was found during histological examination.
Owing to the effectiveness of polychemotherapy, the availability of the tumor
markers hCG and AFP (which can also be used to detect recurrent disease), the
increase in reliability of clinical staging by CT scanning and the disadvantages of
RPLND, it was decided at the Groningen clinic to adopt Peckham’s ’wait-and-see
policy’ in patients with stage I NSTGCT in 1982.51 This meant that after
orchidectomy, these patients entered an intensive outpatient follow-up programme.
Besides physical examination, serum was obtained regularly to monitor tumor
markers and at specific intervals, a chest X-ray was taken and CT scanning of
abdomen and chest was performed. In this way, if any metastases developed, they
could be detected at a early stage. Although the recurrence rate in patients with a
stage I primary tumor was 25%, they could all be treated effectively with
cisplatin-based polychemotherapy.
In order to be able to identify patients with an increased risk of disease
recurrence, a search was made for unfavourable prognostic factors. The literature
mentions various unfavourable prognostic factors, such as the presence of
vascular invasion or lymphatic invasion, the histological tumor (pT) stage, the
presence of embryonal carcinoma or teratoma in the primary tumor and increased
tumor marker levels prior to orchidectomy. Some clinics have suggested adjuvant
treatment with chemotherapy or radiotherapy for the subgroup of patients with
clinical stage I NSTGCT and one or more of these risk factors. At present, the
primary treatment for patients with stage II or more advanced stage disease in
Europe, is orchidectomy and combination chemotherapy. Occasionally, patients
with stage IIA or IIB NSTGCT undergo orchidectomy followed by nerve-sparing
RPLND, if necessary supplemented by chemotherapy. This approach is mainly
applied in the USA.52
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The cytotoxic drugs used to treat patients with disseminated NSTGCT are
administered intravenously. To limit the renal toxicity of cisplatin, intravenous
prehydration and posthydration are necessary. In practise this means that the
patient retains an intravenous needle for 24 hours per day for seven consecutive
days. An alternative approach was introduced at the end of the 1970s: the patients
were provided with an arteriovenous shunt (A-V shunt) in the wrist to facilitate
the administration of the chemotherapy and infusion fluids.53,54 This produced
widening of the veins because of arterialisation and made them easier to puncture.
An additional advantage was that the rapid flow of blood through the vein quickly
diluted the cytotoxic drugs and reduced the irritation to the vessel walls.
Unfortunately, the life span of the A-V shunts proved to be very short in practise,
namely 2-12 months. Moreover, complications, such as thrombosis and infection,
occurred fairly frequently.54 At the beginning of the 1980s, the Venous Access
Port (VAP) became available. This subcutaneous access system could remain in
situ longer and was associated with far less morbidity than an A-V shunt.
Therefore, the VAP formed a considerable advance for patients with an NSTGCT
that had to be treated with cisplatin-based polychemotherapy.
After completion of chemotherapy, the staging examinations are repeated. Fairly
often residual tumor is detected. The treatment policy for such residual disease
after chemotherapy depends on whether the primary tumor was a seminoma or a
nonseminoma. Residual disease in patients with a disseminated seminoma can be
treated with surgery,55 radiotherapy56 or they can enter a wait-and-see
programme.57-59 At the University Hospital Groningen, the wait-and-see policy is
generally employed for these patients.
If the primary tumor was an NSTGCT and the tumor markers have normalised,
but residual disease is present or suspected, the patients usually undergo
evaluative surgery. Surgery plays a major role in judging the outcome of
chemotherapy. The histology of residual lesions is of importance to determine
whether any further treatment is necessary. If the residual lesions only contain
necrosis or fibrosis, resection does not have any therapeutic consequences;
however, if the lesions contain viable cancer, the patient receives additional
polychemotherapy. There is a great risk that if the primary tumor contained a
teratoma component, the residual lesions will contain mature teratoma.
Histologically, mature teratoma gives the impression of being benign, but
cytogenetically it is malignant.60,61 In addition, it has been found that residual
mature teratoma can develop into large, usually cystic tumors that eventually
compress the adjacent organs and give rise to serious complications. This
21
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phenomenon is referred to as the "Growing Teratoma Syndrome".62 A mature
residual lesion can also develop into a second non-germ cell malignancy.63 With
the aim of minimizing the risk of the growing teratoma syndrome or a second
malignancy, relaparotomy was performed at the University Hospital Groningen,
irrespective of the radiological findings, with resection of any palpable
abnormalities, between 1978 and 1984.64 Thoracotomy was only carried out if
there was radiological evidence of lung metastases. Partly based on reports in the
literature, the policy of re-laparotomy after chemotherapy was discontinued at the
end of 1986 in patients without signs of residual lesions on their CT scans and
whose primary tumor had not contained a teratoma component.64 On the basis of
prognostic models, attempts have recently been made in the literature to sharpen
the indications for RPLND after polychemotherapy.65 Additionally, trials are
underway to investigate whether new diagnostic methods, such as MRI and
Positron Emission Tomography (PET scanning) can be used to predict the
histology of metastases.12,66
I.3 RESEARCH QUESTIONS
The above shows that over the years, the role of surgery has been influenced
considerably by the many new developments in diagnosis and treatment of
patients with testicular tumors. Since the publication of Wobbes’ thesis in 1981,
RPLND as the only curative option for these patients has evolved into adjuvant
surgery after chemotherapy.67 This thesis describes the present role of surgery in
the treatment of patients with malignant testicular germ cell tumors. The studies
focus chiefly on the surgical treatment and follow-up of patients with NSTGCT.
At present, there is a more than 15 years of experience with the ’wait-and-see
policy’ in patients with clinical stage I NSTGCT. A study was performed to
investigate whether or not this is a reliable policy; the results are described in
Chapter II. Details are given about the recurrence rate of patients who entered
the wait-and-see programme, the interval between orchidectomy and the
development of metastases and the way in which the metastases were detected.
A search was then made for unfavourable prognostic factors that could predict the
development of metastases. Also was examined whether it is necessary to
continue follow-up for ten years after orchidectomy.
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The results of a study on the normal values and half-life of a new serum tumor
marker, TRA-1-60, are described in Chapter III. AFP and hCG are the standard
tumor markers, so it was of interest to determine whether TRA-1-60 has any
additional value in the follow-up of patients with clinical stage I NSTGCT. An
increased serum TRA-1-60 value at the time of orchidectomy was examined as a
potential unfavourable prognostic factor for the development of metastases.
Chapter IV describes the perioperative and late complications of the use of a
VAP as an access system for chemotherapy in patients with disseminated
testicular cancer. On the basis of a homogeneous group of patients, attempts were
made to identify factors that could predict the development of complications.
The importance of determining the histology of metastases after treatment with
orchidectomy and polychemotherapy must be weighed against the complications
and risks of surgical intervention. In Chapter V the advantages and disadvantages
of resecting residual lesions from the retroperitoneum are discussed. Factors that
might have predictive value regarding complications were evaluated.
On analogy with Chapter V, Chapter VI examines the advantages and
disadvantages of resecting residual lesions from the lungs. An additional question
is whether the indication for resecting residual lesions from the lungs should also
depend on the histological results of the retroperitoneal lesions.
In summary, this thesis addresses the following research questions:
1. Is the current policy for all patients with a clinical stage I NSTGCT
justified, or should it be modified, possibly only for certain subgroups?
2. What is the significance and value of the new serum tumor marker
TRA-1-60 in patients with clinical stage I NSTGCT?
3. What perioperative and late complications are associated with placing a
subcutaneous access system for polychemotherapy in patients with
disseminated testicular germ cell tumors?
4. What are the advantages and disadvantages of surgical resection of
23
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residual retroperitoneal lesions after polychemotherapy in patients with
disseminated NSTGCT?
5. What are the advantages and disadvantages of surgical resection of
residual pulmonary lesions after polychemotherapy in patients with
disseminated NSTGCT?
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ABSTRACT
A wait-and-see policy for patients with stage I nonseminomatous testicular germ
cell tumors (NSTGCT) was evaluated in a prospective study. The frequency and
time of recurrence, detection of recurrence and presence of unfavourable
prognostic factors were investigated. During the period 1982 to 1992, 154
patients with stage I NSTGCT (median age 29 years) underwent orchidectomy
and were monitored at follow-up evaluation with physical examinations, alpha-
fetoprotein (AFP) and human chorionic gonadotrophin (hCG) levels, chest X-rays
(CXR) and computed tomography (CT) scans of the abdomen and chest.
Multivariate logistic regression analyses were performed to identify prognostic
factors. During a median follow-up period of 7 years (range 2-12), recurrence
was found in 42 patients (27.3%). All cases of recurrence were detected within
two years, 90% in the first year after orchidectomy. In 29 patients (69.0%),
recurrence was detected in the abdominal lymph nodes. Nine patients (21.4%)
had metastases in the retroperitoneum and the mediastinum and/or the lungs and
four patients (9.6%) had metastases only in the mediastinum or lungs. The
majority of recurrences (97.6%) were detected by tumor markers and CT scans.
Recurrence was related to the presence of vascular invasion, embryonal
carcinoma (E), an elevated preoperative hCG level and the absence of mature
teratoma (M). Only vascular invasion was an independent risk factor. After
polychemotherapy treatment for recurrence, the survival rate in the total group
was 98.7%. The wait-and-see policy is a reliable method for follow-up monitoring
of patients with stage I NSTGCT. Even in patients with unfavourable prognostic
factors, it is justified to await the possible appearance of metastases. For the
future it is recommended that CXR be omitted from the schedule, and it might be
feasible to discontinue the follow-up evaluations after five years.
INTRODUCTION
In the 1970s, cisplatin became available in various chemotherapy combinations.
This considerably improved the prognosis of patients with disseminated
nonseminomatous testicular germ cell tumors (NSTGCT), especially in the lower
stages.1,2 In addition, the introduction of computed tomography (CT) scanning of
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the abdomen and chest enabled more accurate clinical staging than could be
achieved with the former diagnostic procedures: lymphangiography and lung
tomography.3,4 Before the introduction of cisplatin patients with stage I NSTGCT
were treated with radical retroperitoneal lymph node dissection (RPLND)5,6 or
external beam radiotherapy (EBRT) of the para-aortic and ipsilateral pelvic lymph
nodes.7 A major complication from RPLND had been retrograde ejaculation and
EBRT may induce a radiation enteritis. The high cure rates obtainable with
cisplatin-based chemotherapy, especially in patients with low stage disease, the
availability of serum tumor markers for NSTGCT and the increased accuracy of
the CT scanning, as well as the adverse effects associated with RPLND and
EBRT, led to the initiation of a number of studies to assess the utility of
surveillance for stage I disease. Peckham and collegues introduced in 1979 this
management policy.8 They found a recurrence rate of 17% in 53 patients after a
median follow-up of 15 months. They argued that the proportion of patients
curable with orchidectomy alone should be 60-80%, and that if recurrence
occurred, effective chemotherapy was available.
After orchidectomy for patients with a clinical stage I NSTGCT without any
evidence of metastases the wait-and-see policy was commenced. At the regular
outpatient check-ups, the patients underwent a physical examination, evaluation of
the serum tumor markers alpha-fetoprotein (AFP) and human chorionic
gonadotrophin (hCG) and a chest X-ray. At various intervals, CT scans were
taken of the abdomen and chest. In this way, any retroperitoneal, mediastinal
and/or lung metastases could be detected early. Also several other groups have
reported their preliminary or mature data. Recurrences occured at a rate of 16% to
35.2%9-15 after a median follow-up varying between 10 and 64 months. Most
recurrences, however, occurred within 12 months. Among the patients who
recurred, disease-free survival after treatment is 92% to 100%. Later on, efforts
have been directed toward the identification of prognostic factors that may predict
the likelihood of recurrence. The unfavourable significance of vascular or
lymphatic invasion,12,13,15-18 histology13,16,18 and local tumor extension13,19 has been
generally accepted.20 This had led to the institution of trials using adjuvant
chemotherapy in patients with high risk stage I disease.12,21
In the Netherlands, the University Hospital Groningen has been employing the
wait-and-see policy since 1982.22,23 This prospective study describes the ten years
of experience with this policy in patients with stage I NSTGCT. The number of
patients with recurrence was evaluated, how this recurrence was detected was
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described and the number of months until recurrence was determined. Also, the
presence of any unfavourable prognostic factors which might be related to
recurrence were investigated. The aim of the study was to examine the adequacy
of a wait-and-see policy for patients with a stage I NSTGCT. Advice and
recommendations regarding follow-up evaluation are given.
PATIENTS AND METHODS
In the period 1982 to 1992, 154 patients with clinical stage I NSTGCT (median
age 29 years; range 15-66) were treated at the University Hospital Groningen, the
Netherlands. All of the patients underwent orchidectomy and at staging there was
no evidence of regional and/or distant metastases. Clinical staging was performed
as described by Peckham et al24 with the aid of physical examination, chest X-ray,
serum tumor markers AFP and hCG, and CT scanning of the chest and abdomen.
Values for AFP of >10 µg/l and for hCG of ≥2.0 µg/l were considered to be
elevated. If the serum tumor markers were elevated before the orchidectomy, they
were expected to normalize postoperatively in accordance with the half-life times.
The half-life times for AFP and hCG are six days and two days, respectively. In
the initial years of the study period, bilateral lymphangiography also formed part
of the staging procedure. Since 1986, only CT scanning has been performed
owing to the limited reliability of lymphangiography and its complicated
interpretation.3,25
In the period 1982-1983, an explorative laparotomy was carried out in
conjunction with the orchidectomy to make a definite diagnosis regarding the
presence or absence of retroperitoneal lymph node metastases. On the basis of an
interim analysis, it was decided from 1984 on to perform this laparotomy only if
radiologic findings were inconclusive. If there were no palpable pathologic
retroperitoneal lymph nodes these patients were classified as stage I and still
entered the study.23
The tumors were classified in accordance with the nomenclature of the World
Health Organisation (WHO),26 which distinguishes the following histological
components in nonseminomatous testicular tumors: embryonal carcinoma (E),
choriocarcinoma (C), yolk sac tumor (Y) and teratoma. Teratomas can contain
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mature or immature components: mature teratoma (M) and immature teratoma (I).
The nonseminomas are usually composed of more than one histological subgroup,
sometimes with a seminoma (S) component.27 Data on the diameter of the
primary tumor and the presence or absence of vascular invasion were obtained
from the surgical specimens. pT stage was determined according to the
International Union Against Cancer (UICC) 1978 edition.28
Outpatient check-ups were performed according to a strict schedule (Table 1).
Physical examination and serum AFP and hCG determinations were performed at
each visit. A chest X-ray and CT scanning of the chest and abdomen were carried
out at regular intervals. After ten years, the follow-up was considered to be
complete and the patients were discharged from further evaluations. The patients
with recurrence were treated with cisplatin-based combination chemotherapy.
Table 1. Follow-up schedule of the wait-and-see policy for patients with
stage I NSTGCT (1982-1992)
Year 1 Every 4 weeks: PE, TM
Every 8 weeks: PE, TM, CXR
Every 3 months: PE, TM, CTa, CTc
Year 2 Every 8 weeks: PE, TM
Every 3 months: PE, TM, CXR
Every 6 months: PE, TM, CTa, CTc
Year 3 Every 3 months: PE, TM, CXR
Every 12 months: PE, TM, CTa, CTc
Years 4 and 5 Every 6 months: PE, TM, CXR
Years 6, 7, 8, 9 and 10 Every 12 months: PE, TM, CXR
Abbreviations: PE, physical examination; TM, tumor markers AFP and hCG; CXR, chest
X-ray; CTa, computed tomogram of the abdomen; CTc, computed tomogram of the chest.
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Statistical analysis
Univariate analyses were performed on differences in clinical characteristics
between the two subgroups ’recurrence’ and ’no-recurrence’ with Student’s t test
for continuous variables and by means of the Chi-square test for categorical
variables. Fisher’s exact test was used in case of small numbers. Multivariate
logistic regression analysis was used to examine correlations between variables
with possible prognostic significance and the appearance of recurrence;29 the
dependent variable was recurrence within two years. Independent variables were
age, tumor location (left or right), maximum diameter of the primary tumor,
preoperative elevation of AFP and/or hCG, histological components of the
primary tumor, the presence of vascular invasion in the primary tumor and pT
stage. Age and maximum diameter of the primary tumor were continuous
variables, while the remaining variables were dichotomous (0=absent, 1=present).
By including all of the independent variables simultaneously in the regression
model, we could establish the relationship between each separate variable and the
appearance of recurrence. No-recurrence acted as a reference for the dependent
variables, while the absence of a particular characteristic acted as a reference for
the independent variables. To obtain the best fitting regression model, the number
of independent variables was reduced by means of the step-wise elimination of
covariables, with the likelihood-ratio statistic as selection criterion.
Owing to the fact that the maximum diameter of the primary tumor was unknown
in 19 patients, the regression analysis was also carried out without this variable.
The statistical analyses were conducted using the SPSS-PC+ (V4.0) software
package (SPSS inc., Chicago, Ill., USA.). Test statistics and odds ratios were
considered to be statistically significant at P≤.05.
RESULTS
Between January 1982 and December 1991, 154 patients with clinical stage I
NSTGCT were treated at the University Hospital Groningen. Before 1984 all
patients who entered the study had undergone an explorative laparotomy. Since
1984, four patients have undergone laparotomy because the findings on CT-scans
were inconclusive: i.e. no palpable abnormalities were found during laparotomy.
The median follow-up was seven years (range 2-12 years). The frequencies of the
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various separate histological basic components in the primary tumors are shown
in Table 2. These results resemble the results of other authors also using the
WHO-classification.30 Choriocarcinoma (C) was present in 22 patients (14.3%),
embryonal carcinoma (E) in 132 patients (85.7%), immature teratoma (I) in 56
patients (36.4%), mature teratoma (M) in 101 patients (65.6%), seminoma (S) in
49 patients (31.8%) and yolk sac tumor (Y) in 60 patients (39.0%). The most
frequent mixed tumors were composed of S plus E with or without Y and/or M
and/or I (41 patients), E plus M with or without I (27 patients) and E plus Y with
or without M and/or I (26 patients). In 25 patients, the orchidectomy specimen
consisted of one single tumor component: embryonal carcinoma in 16 patients
(10.4%) and mature teratoma in 9 patients (5.8%).
During the course of follow-up, metastases were found in 42 patients (27.3%).
Recurrence was diagnosed after a median duration of four months (average 5.7
months, range 2-24 months). Ninety per cent of the recurrences, i.e. 38 out of 42,
were detected within one year. All of the cases of recurrence were discovered
within two years of the orchidectomy.
After orchidectomy, 27 patients (64.2%) developed retroperitoneal lymph node
metastases (stage II) and two patients (4.8%) developed inguinal lymph node
metastases. One of the latter patients was later also found to have retroperitoneal
lymph node metastases. Also, of the 42 patients with recurrence, 29 had stage II
disease at the time of detection. In nine patients (21.4%), metastases had
developed in the retroperitoneum as well as in the mediastinum and/or lungs
(stage III or IV). In two patients (4.8%), metastases were only found in the
mediastinal lymph nodes (stage III) and in two other patients (4.8%) only in the
lungs (stage IV). Of the four patients who developed recurrence in the second
year after orchidectomy, three had retroperitoneal metastases (stage IIb, IIc and
IIc, respectively) and one had mediastinal metastases (stage III).
In 17 patients, the CT scans showed abnormalities at the same time as the tumor
markers became elevated (40.5%), while in eight patients (19.0%) the diagnosis
of recurrence was made on the basis of elevated serum tumor markers only. In all
these patients elevated markerlevels were confirmed repeatedly. In one patient
(2.4%) the only expression of recurrence was a histologically proven inguinal
lymph node metastasis found during physical examination. In 16 patients
recurrence was detected by radiological abnormalities on the CT scans (38.1%).
Table 2. Histological findings in the primary tumor
35
Follow-up in Stage I NSTGCT
Components Total (n=154) No Rec.(n=112) Rec.(n=42)
S+E 16 (10%) 10 6
S+E+C+Y+M 1 (0.6%) 0 1
S+E+C+M+I 1 (0.6%) 1 0
S+E+Y 4 (2.6%) 2 2
S+E+Y+M 4 (2.6%) 4 0
S+E+Y+M+I 7 (4.5%) 5 2
S+E+M 1 (0.6%) 1 0
S+E+M+I 7 (4.5%) 5 2
S+E+Y+I 1 (0.6%) 0 1
S+E+I 1 (0.6%) 1 0
S+C 1 (0.6%) 1 0
S+Y 1 (0.6%) 1 0
S+Y+M+I 1 (0.6%) 1 0
S+M 1 (0.6%) 1 0
S+M+I 2 (1.3%) 2 0
E 16 (10%) 11 5
E+C 1 (0.6%) 1 0
E+C+Y 1 (0.6%) 1 0
E+C+Y+M 4 (2.6%) 4 0
E+C+Y+I 2 (1.3%) 2 0
E+C+Y+M+I 5 (3.2%) 3 2
E+C+M 4 (2.6%) 3 1
E+C+M+I 2 (1.3%) 0 2
E+Y 8 (5.2%) 3 5
E+Y+M 8 (5.2%) 6 2
E+Y+M+I 10 (6.5%) 8 2
E+M 16 (10%) 13 3
E+M+I 11 (7.1%) 7 4
E+I 1 (0.6%) 1 0
Y+M+I 1 (0.6%) 1 0
Y+M 2 (1.3%) 1 1
M 9 (5.8%) 8 1
M+I 4 (2.6%) 4 0
Abbreviations: Rec., recurrence; C, choriocarcinoma; E, embryonal carcinoma;
I, immature teratoma; M, mature teratoma; S, seminoma; Y, yolk sac tumor
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In one patient lung metastases were histologically proven. None of the cases of
recurrence were found by means of the chest X-ray. Fourteen patients who
developed radiological changes on CT-scans of abdomen, but without marker
elevation, underwent an exploratory laparotomy before remission induction
chemotherapy was started. Three of these patients also had signs of metastases on
CT-scan of the chest. All fourteen patients had palpable pathologic para-aortic
lymph nodes. In one patient retroperitoneal lymph node metastases caused
hydonephrosis of the left kidney, in this patient no exploratory laparotomy was
done because the clinical appearance and CT-scan of the abdomen were thought
to be conclusive for metastases. This patient and seven out of the fourteen
patients with retroperitoneal recurrence detected only on CT scan, were
relaparotomized after four remission-induction courses with cisplatin based
polychemotherapy. In one case no palpable abnormalities were found and in
seven cases residual tumor was found, and resected. Histologic examination of the
resected specimen revealed necrosis and fibrosis in three cases and mature
teratoma in the other four. Because in the other seven patients radiologically
documented recurrences disappeared completely, surgical evaluation was not
performed.
Table 3 shows a comparison of the characteristics present in the recurrence group
and the no-recurrence group. Univariate comparison of the clinical characteristics
between the group with and the group without recurrence did not reveal any
significant differences in the average age, tumor location, average maximum
diameter of the primary tumor and pT stage ≥2. Of the tumor markers,
particularly the serum hCG level was elevated more frequently in the patients
with recurrence than in those without recurrence; this difference was not
statistically significant (P=.085). Of the histological characteristics of the primary
tumor, embryonal carcinoma was present significantly more often in the patients
with recurrence, whereas mature teratoma was present more often (not significant)
in the patients without recurrence (P=.083). Vascular invasion was present
significantly more often in the recurrence group than in the no-recurrence group:
45.2% versus 15.2%. Multivariate logistic regression analysis was carried out on
all the possible risk factors (n=135; Table 4) and repeated after the only variable
with missing values, i.e. the maximum diameter of the primary tumor, had been
omitted. The exclusion of this variable which was not found to be associated with
the appearance of recurrence using univariate or multivariate analysis, meant that
all the patients could be included in the analyses (n=154; Table 5).
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Table 3. Population characteristics by recurrence status
No Recurrence Recurrence P
(n = 112) (n = 42)
Age, in years (mean±SD) 30±10 29±7 .648
Primary tumor
Location: Left 50 (44.6%) 17 (40.5%) |
Right 62 (55.4%) 25 (59.5%) | .642
Max. diameter, mm (mean±SD) 39.0±19 41.4±18 .505
Preoperative elevated AFP 53 (47.3%) 23 (54.8%) .411
Preoperative elevated hCG 39 (34.8%) 21 (50.0%) .085
Histological findings:
Seminoma 35 (31.3%) 14 (33.3%) .805
Embryonal carcinoma 92 (82.1%) 40 (95.2%) .039
Choriocarcinoma 16 (14.3%) 6 (14.3%) 1.000
Yolk sac tumor 42 (37.5%) 18 (42.9%) .544
Mature teratoma 78 (69.6%) 23 (54.8%) .083
Immature teratoma 41 (36.6%) 15 (35.7%) .918
Vascular invasion present 17 (15.2%) 19 (45.2%) .000
Histologic staging pT≥2 6 (5.4%) 4 (9.5%) .462
In both cases, vascular invasion was the only significant independent risk factor
for the manifestation of recurrence (Odds Ratios 4.28 and 4.06, respectively). In
the patients who were included in the second regression analysis (and not the
first), mature teratoma occurred more frequently, while embryonal carcinoma, an
elevated AFP and an elevated hCG occurred less frequently. In this way, the step-
wise elimination of covariables led to two slightly different models. Logistic
regression analysis with step-wise elimination of covariables in the first case
(n=135) gave rise to the following regression model: y = -1.275 + 0.808 x hCG -
0.793 x mature teratoma + 1.534 x vascular invasion. In the second case (n=154),
the regression model was: y = -2.519 + 1.250 x embryonal carcinoma + 1.445 x
vascular invasion. The two models indicate that recurrence is related to the
presence of vascular invasion (Odds Ratios 4.63 and 4.24, respectively), a
preoperative elevated hCG value (Odds Ratio 2.24), the absence
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of mature teratoma (Odds Ratio 0.45) and the presence of embryonal carcinoma
(Odds Ratio 3.49). The only independent prognostic factor was the presence of
vascular invasion.
Table 4. Multivariate logistic regression analysis of risk factors for
recurrence (n=135)
Independent variable Odds Ratio P
All potential risk factors simultaneously in the model
Age 1.00 .940
Tumor location (Left vs Right) 0.82 .657
Maximum diameter primary tumor 1.01 .517
Preoperative elevated AFP 1.44 .514
Preoperative elevated hCG 2.23 .105
Seminoma present 0.70 .471
Embryonal carcinoma present 2.10 .386
Choriocarcinoma present 0.58 .393
Yolk sac tumor present 1.10 .841
Mature teratoma present 0.38 .082
Immature teratoma present 0.96 .940
Vascular invasion present 4.28 .001
Histologic staging pT≥2 2.34 .321
Model after backward elimination of covariates
Vascular invasion present 4.63 .001
Preoperative elevated hCG 2.24 .062
Mature teratoma present 0.45 .069
Owing to the fact that we found relationships between an elevated AFP and the
presence of choriocarcinoma, yolk sac tumor and mature teratoma, and between
an elevated hCG and the presence of choriocarcinoma, the regression analyses
were also carried out with interaction terms for these variables. However, the
addition of these interaction terms did not produce any significant improvement in
the regression models.
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Table 5. Multivariate logistic regression analysis of risk factors for
recurrence (n=154)*
Independent variable Odds Ratio P
All potential risk factors simultaneously in the model
Age 1.00 .932
Tumor location (Left vs Right) 0.89 .767
Preoperative elevated AFP 1.54 .395
Preoperative elevated hCG 1.84 .178
Seminoma present 0.98 .965
Embryonal carcinoma present 2.67 .228
Choriocarcinoma present 0.60 .403
Yolk sac tumor present 0.97 .949
Mature teratoma present 0.46 .136
Immature teratoma present 1.20 .701
Vascular invasion present 4.06 .001
Histologic staging pT≥2 1.54 .576
Model after backward elimination of covariates
Vascular invasion present 4.24 .000
Embryonal carcinoma present 3.49 .110
* Maximum diameter of primary tumor not included because of missing values
Of the 42 patients with metastases, 40 went into complete remission after
treatment with cisplatin-based polychemotherapy, with or without explorative
surgery for resection and histological examination. Those patients in which no
viable cancer was found in resected specimens, were classified as complete
responders. One patient refused to be treated with chemotherapy. The other
patient only had a local inguinal lymph node metastasis on the left side. After
excision of this small metastasis, no further evidence could be found of distant
metastases, so there was no longer any indication for chemotherapy.
Two of the patients with recurrence died. One of these patients was the one who
had refused chemotherapy; he died 41 months after the orchidectomy. The other
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patient went into complete remission after cisplatin-based polychemotherapy for
inguinal, retroperitoneal and lung metastases, but he developed a second
recurrence eleven months later. The second recurrence was also accompanied by
lung metastases, for which he received second line polychemotherapy. He died
twenty months after the orchidectomy. The ultimate disease-free survival of the
154 patients with stage I NSTGCT who were monitored with the wait-and-see
follow-up policy was 98.7%; two out of the 154 patients (1.3%) died.
DISCUSSION
Over a 10-year period (median follow-up time 7 years), this study group
comprised 154 patients with a clinical stage I nonseminomatous testicular germ
cell tumor. A total of 42 patients (27.3%) developed recurrence after a median
follow-up of 4 months (range 2-24 months). At the time of detection of
recurrence, the majority of patients (69.0%) had stage II disease, i.e. the
metastases were located in the abdominal lymph nodes: in the retroperitoneal
and/or inguinal lymph nodes. In this series, all the cases of recurrence were found
within two years after the orchidectomy. Other authors have reported cases of
dissemination after two years,14,31 with rates of up to 7%. After five years, the
appearance of recurrence is extremely rare. In such cases, if the histology of the
recurrence does not exactly match that of the primary tumor, it is worth
considering whether the second tumor is a new primary extragonadal germ cell
carcinoma.32 Forty patients had to be treated with cisplatin-based
polychemotherapy during the course of the follow-up. With a median follow-up
duration of seven years, a disease-free survival of 98.7% was achieved.
Serum tumor markers as well as CT scanning of the abdomen and chest played a
major role in the detection of recurrence. Both were indispensable for the early
detection of metastases, so that treatment with polychemotherapy could be started
at an early stage. In eight patients, the diagnosis of recurrence was made purely
on the basis of elevation of one or both serum tumor markers. In one of these
patients, palpable inguinal lymph nodes were found shortly afterwards and in the
other seven, the CT scans became abnormal after 2, 2, 3, 3, 4, 5 and 20 months,
respectively. These patients received polychemotherapy after the metastases had
been confirmed radiologically using CT. Prior to the orchidectomy, elevated
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values of one or both serum tumor markers were found in 93 patients (60.4%).
Nine of these patients developed recurrence (21.4%), however the tumor markers
were not elevated when the recurrence was found. The opposite was observed in
six patients (14.3%) who had normal serum tumor marker values before
orchidectomy but elevated values at the time of recurrence. This discordance in
the behaviour of tumor markers has been described by other authors14,15,31,33,34 and
has been reviewed.35 In cases where the primary tumor had exclusively produced
AFP (6 patients), the metastases caused either an elevation in the AFP values (3
patients) or no increase in tumor marker values. The same was valid for the
tumors which had exclusively produced hCG (4 patients): if the metastases had
produced a tumor marker (3 patients) it was always exclusively hCG.
CT scanning was also very helpful in the detection of recurrence. In only four
patients CT scans were inconclusive during follow-up. Because a recurrence could
not be excluded completely, these four patients underwent diagnostic laparotomy.
However, no palpable abnormalities were found at laparotomy and none of these
patients developed recurrence during follow-up.
The chest X-ray was not found to have much value in this series. Abnormalities
on the chest X-ray never formed the first indication of recurrence. Of the 13
patients with lung metastases, abnormalities were only visible on the relevant
chest X-ray in two cases. Therefore, it seems to be not worthwhile to take regular
chest X-rays in the follow-up of patients with stage I NSTGCT.
This study and others have shown that the presence of vascular invasion is an
unfavourable prognostic factor.12,13,15-18,21,36 pT stage has also been identified as a
prognostic factor by several authors, especially tumor invading into the tunica
albuginea, rete epididymis or spermatic cord: pT≥2.13,35,37 However this prognostic
factor was found in univariate analyses. In this study pT-stage was not found to
be predictive of subsequent recurrence, in multivariate nor in univariate
comparison. An embryonal carcinoma component in the primary tumor has also
often been mentioned as an independent risk factor for the development of
recurrence.18,30,36 In this study, only univariate comparison of the clinical
characteristics between the recurrence group and the no-recurrence group showed
that embryonal carcinoma occurred significantly more often in the recurrence
group.In the literature, other unfavourable prognostic factors include: the absence
of yolk sac tumor,21 lymphatic invasion12,21,30,38,39 and the absence of teratomatous
elements.16 In this study we found that the development of recurrence was related
to the presence of vascular invasion, embryonal carcinoma, a pre-orchidectomy
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elevated serum hCG value, and the absence of mature teratoma. On the basis of
the list of unfavourable prognostic factors, it is possible to select a group of
patients from those with stage I NSTGCT who are at increased risk for
recurrence. Some authors have recommended adjuvant treatment for these
patients.12,21 However, retroperitoneal lymph node dissection,40 adjuvant
chemotherapy41 or radiotherapy14 cannot prevent the development of recurrence in
all cases. In this series of patients, the administration of adjuvant polychemo-
therapy to for example all the patients with vascular invasion in the primary
tumor would have meant the ’overtreatment’ of 17 out of the 36 patients.
The wait-and-see policy for patients with stage I NSTGCT is a safe and suitable
follow-up method. With this approach, about three quarters of the patients could
be spared RPLND or EBRT. On the basis of the results of this study, we are of
the opinion that it is justified to follow a wait-and-see policy even in patients
with stage I NSTGCT who are at increased risk for developing recurrence.
The compilation of these results has led to the new wait-and-see follow-up
schedule for patients with stage I NSTGCT shown in Table 6.
Table 6. Recommendations for future follow-up schedule
of patients with stage I NSTGCT
Year 1 Every 4 weeks: PE, TM
Every 3 months: PE, TM, CTa, CTc
Year 2 Every 8 weeks: PE, TM
Every 6 months: PE, TM, CTa, CTc
Year 3 Every 3 months: PE, TM
Every 12 months: PE, TM, CTa, CTc
Years 4 and 5 Every 6 months: PE, TM
Every 12 months: PE, TM, CTa, CTc
Abbreviations: PE, physical examination; TM, tumor markers AFP and hCG;
CTa, computed tomogram of the abdomen; CTc, computed tomogram of the chest.
The chest X-ray has been omitted from this schedule because the relevance for
the detection of recurrence was questionable. Furthermore, it is our view that it
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is accountable to discontinue the follow-up evaluations after five years because no
cases of recurrence were found after two years. Other changes to the schedule, for
example, lengthening the interval between two follow-up visits, would not be
wise, particularly in the first two years, because in our experience, dissemination
can be rapidly progressive. This would involve the risk of detecting recurrence at
a later stage, with a decreasing chance of being able to cure the patient with
polychemotherapy.42
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ABSTRACT
TRA-1-60 is a new tumor marker for embryonal carcinoma-positive non-
seminomatous testicular germ cell tumors (NSTGCT). Upper normal reference
value (RV) and serum half-life time (T½) were determined. The value was
determined in the follow-up of 154 patients with stage I NSTGCT. TRA-1-60 was
measured in normal controls (n=100) to determine RV and in patients without
recurrence for T½. In all patients TRA-1-60 was determined at the time of
orchidectomy. In 42 patients with recurrence, values were also evaluated one
month before and at the time of CT-confirmed recurrence. Predictive values and
survival probability were examined and compared to AFP and hCG. RV was 230
U/ml and T½ 9.5 days. Elevated TRA-1-60 at the time of orchidectomy was not
associated with recurrence. One month before recurrence, 21 of 42 patients had
elevated TRA-1-60 levels (50%); 10 were negative for both AFP and hCG. At the
time of recurrence, 24 patients had elevated TRA-1-60 levels (57.1%); nine were
negative for AFP/hCG. Patients with TRA-1-60 levels of >500 U/ml had a poorer
recurrence-free survival probability (P=.015). TRA-1-60 is useful in the follow-up
of stage I NSTGCT. The combination of AFP, hCG and TRA-1-60 may improve
the early detection of recurrence.
INTRODUCTION
For many years, it has been known that nonseminomatous testicular germ cell
tumors (NSTGCT) may secrete human chorionic gonadotrophin (hCG) and alpha-
fetoprotein (AFP), which are now the principal testicular serum tumor markers in
widespread clinical use. Diagnosis, staging and follow-up of patients with these
tumors have been aided considerably by assaying these markers.1-5 In the past few
years, the patterns of secretion before, during and after treatment have been
extensively studied and described.6-9 Some understanding of the underlying
biological implications of marker production has been reached. Despite this, the
use of AFP and hCG is not ideal, because at least 20% of the patients with an
NSTGCT do not produce these markers.10 Therefore, in recent years, much effort
has been devoted to searching for new tumor markers.
In 1984, Andrews et al. found that the Terato Related Antigen monoclonal
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antibody (TRA-1-60), raised against embryonal carcinoma cells, recognizes a
high-molecular-weight glycoprotein that is expressed on the surface of embryonal
carcinoma progenitor cells.11,12 In 1991, Marrink et al. developed a serum
immunoenzymometric assay for the detection of a TRA-1-60 reactive antigen.13
This antigen is released into the serum of patients with embryonal carcinoma-
positive NSTGCT.
The purpose of this study was to determine whether the TRA-1-60 antigen has
any additional value as a tumor marker to hCG and AFP in the follow-up of
patients with clinical stage I NSTGCT. The upper normal reference value and the
serum half-life of TRA-1-60 were determined. It was also investigated whether an
elevated level of TRA-1-60 at the time of unilateral orchidectomy was an
unfavourable prognostic factor that might be related to recurrence.
PATIENTS AND METHODS
At the University Hospital Groningen, the Netherlands, serum samples were
obtained from all consecutive patients with clinical stage I NSTGCT treated
according to the wait-and-see policy between 1982 and 1992.14 All the patients
underwent orchidectomy and did not have any evidence of regional and/or distant
metastases at clinical staging. Clinical staging was performed as described by
Peckham et al,15 with the aid of physical examination, chest X-rays, tumor marker
assays of AFP and hCG and CT scans of the chest and abdomen. Tumors were
classified in accordance with the nomenclature of the World Health
Organisation;16 the pT stage was determined according to 1978 International
Union Against Cancer criteria.17 Outpatient follow-up evaluations were performed
according to a strict schedule and serum AFP and hCG determinations were
performed at each visit. After ten years, the follow-up period was considered to
be complete and patients were discharged from any further evaluations. During
this period, 42 out of the 154 patients had developed a recurrence, all within two
years of the orchidectomy.14 These patients were therefore treated with cisplatin-
based combination chemotherapy.18,19
Serum samples were obtained before and/or as soon as possible after
orchidectomy from all 154 patients for the determination of tumor marker
concentrations. TRA-1-60 levels were included in the statistical analyses if they
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had been determined from serum samples obtained before or ≤ 10 days after
orchidectomy. From the 42 patients who developed a recurrence, serum samples
were also obtained at the time that recurrence was confirmed by CT and one
month before recurrence. In the patients who had elevated levels of TRA-1-60 at
the time of recurrence, TRA-1-60 levels were also determined during and after
polychemotherapy treatment. TRA-1-60 values were compared to those for AFP
and hCG determined in the same serum samples.
In the TRA-1-60 assay, the antigen was incubated with excess TRA-1-60
antibody, after which the antigen/antibody complex was precipitated by 2.5%
polyethylene-glycol (PEG). The non-bound antibodies in the supernatant were
subsequently transferred to antigen-coated wells in a microtiter plate. The amount
of unbound antibody was then quantified by its ability to bind to the coated
antigen as detected by a peroxidase-coupled second antibody.13,20 Absorbance was
measured at 492 nm using a Titertek Multiscan (Flow, Irvine, UK). Thus, in this
indirect assay, the extinction measured was inversely related to the amount of
antigen present in the original sample. Results were computed according to
Rodbard et al21 and quantified in arbitrary units per millilitre (U/ml). To
determine the upper normal reference value, TRA-1-60 was measured in a healthy
male population of normal controls (n=100), age-matched to the tumor
population. Logarithmic transformation (natural logarithm) of TRA-1-60 levels
was performed to approximate a normal distribution. The upper normal reference
value was calculated by taking the antilog of the geometrical mean, i.e. antilog of
mean ln TRA-1-60, plus twice its standard deviation.22,23 Serum AFP and serum
hCG were determined by immunoassay.24 AFP and hCG values were considered
to be elevated at >10 µg/l and ≥2 µg/l, respectively.
To determine the serum half-life (T½) of TRA-1-60, serum samples were
obtained from patients with a clinical stage I NSTGCT without recurrence.
Only the serum samples of patients who had elevated levels of TRA-1-60 of
>850 U/ml and elevated levels of AFP and/or hCG were used. From the patients
with elevated levels of AFP and/or hCG, samples for tumor marker assays were
obtained two or three times a week after orchidectomy until normalisation. During
follow-up, AFP and hCG determinations were performed every four weeks. If the
AFP and/or hCG levels in these sera normalized postoperatively in exact
accordance with the half-life for AFP of 6 days and hCG of 2 days, it was
assumed that the TRA-1-60 levels had also normalized in accordance with its
half-life time. The TRA-1-60 half-life time was calculated using the method




Log transformation (natural logarithm) was performed on tumor marker levels, to
approximate a normal distribution. Geometric means were calculated by taking
the antilog of the means of these log-transformed tumor marker levels.
Differences in mean tumor marker levels between the two subgroups of patients
with recurrence and those without recurrence were tested by means of the Student
t-test in the case of continuous variables. Differences in dichotomous variables
between the two subgroups of patients with recurrence and those without
recurrence were tested by means of the Chi-square test. Fisher’s exact test was
used in the case of small numbers.23
Recurrence-free survival probabilities of the subjects with normal and those with
elevated tumor marker levels were determined with Kaplan-Meier curves.
Differences in survival probabilities were analysed by the logrank test. Follow-up
started at the time of orchidectomy and ended at the time of CT-confirmed
recurrence in the patients with recurrence. In the patients without recurrence,
follow-up ended ten years after orchidectomy or on 1 January 1995. Cox
regression analysis was used to evaluate the independent associations between
elevated tumor markers and recurrence, adjusted for the influence of other,
previously published covariates: age, tumor location (left or right), histological
components of the primary tumor, presence of vascular invasion in the primary
tumor, and the pT stage.9 Age and tumor markers were used as continuous
variables, while the remaining variables were dichotomized.
Differences were considered to be statistically significant at P<.05. Hazard ratios
were considered to be statistically significant if the 95% confidence interval did
not contain the value 1. The statistical analyses were conducted using the SPSS-
PC+ (version 4.0) software package (SPSS Inc, Chicago, IL, USA).
RESULTS
The mean TRA-1-60 antigen level in the healthy controls was 77.0 U/ml, median
61.5 U/ml (range 20-268 U/ml, n=100). The geometric mean was 61.9 U/ml,
standard deviation 1.9 U/ml. The upper normal reference value for TRA-1-60 was
calculated and after back-transformation, established at 230 U/ml (antilog of ln
61.9 + 2 x ln 1.9).
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In 65 out of the 154 patients, serum samples were available from before and/or
≤10 days after orchidectomy. A total of 35 of these 65 patients had an elevated
level of AFP and/or hCG. Ten of these patients developed a recurrence, which
left 25 patients with elevated levels of AFP and/or hCG without recurrence. From
these 25 patients, five also had TRA-1-60 levels of > 850 U/ml in the first serum
sample. The serum samples of these five patients were used to determine the T½
of TRA-1-60; the median follow-up duration was 10 years, range 7 to 11 years.
The mean serum half-life time was 9.5 days, median 9.5 days (range 8.5 - 10.5
days).
In the 65 patients whose serum samples were available at the time of
orchidectomy, 17 patients developed a recurrence. In the remaining 48 patients
without recurrence, one patient with a very high level of AFP (970 µg/l) and one
patient with a very high level of hCG (1217 µg/l) were considered as outliers and
were excluded from the analyses. Statistical significance was not influenced by
this. Thus, our analyses were performed on a population of 63 patients: 17 with
recurrence and 46 without recurrence.
Tables 1a and 1b list comparisons of the tumor markers AFP, hCG and
TRA-1-60 in the study population, stratified by the recurrence status. For all the
tumor markers, the geometric mean was higher in the patients with recurrence
than in those without. However, these differences were not statistically significant
(Table 1a).
Table 1a. Tumor markers at the time of orchidectomy in
relation to the recurrence status (continuous)
No Recurrence Recurrence
Tumor marker n=46 n=17 P
Geometric mean
AFP (µg/l) 10.8 18.3 .243
hCG (µg/l) 1.0 1.5 .309
TRA-1-60 (U/ml) 223.4 328.4 .089
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Dichotomous comparison showed that the proportion of elevated tumor marker
levels was higher in the patients with recurrence than in those without. Again,
none of these differences were statistically significant (Table 1b).
Table 1b. Tumor markers at the time of orchidectomy in
relation to the recurrence status (dichotomous)
No Recurrence Recurrence
Tumor marker n=46 n=17 P
Tumormarker elevated
AFP (%) 21 (45.7) 10 (58.8) .353
hCG (%) 7 (15.2) 5 (29.4) .279
TRA-1-60 (%) 23 (50.0) 10 (58.8) .534
Predictive values of the tumor markers AFP, hCG and TRA-1-60 in these 63
patients are compared in Table 2.
Table 2. Predictive values of the tumor markers
Characteristic AFP hCG TRA-1-60
Sensitivity 0.59 0.29 0.59
Specificity 0.54 0.85 0.50
Positive Predictive Value 0.32 0.42 0.30
Negative Predictive Value 0.78 0.76 0.77
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Serum TRA-1-60 and AFP had a similar sensitivity (0.59) and specificity (0.50;
0.54). Serum hCG had a low sensitivity (0.29) with a high specificity (0.85).
Positive and Negative Predictive Values for these three tumor markers were
basically the same. Thus, AFP and TRA-1-60 best detected disease and hCG best
detected the absence of disease in this group of patients with clinical stage I
NSTGCT. However, overall AFP, hCG and TRA-1-60 were of comparable value.
The influences of AFP, hCG and TRA-1-60 on the recurrence-free survival
probability were determined by means of Kaplan-Meier survival analyses. Patients
with elevated levels of TRA-1-60 of >230 U/ml in the first serum sample did not
have a significantly poorer recurrence-free survival probability. The same was
true for elevated levels of AFP and hCG. Only the patients with elevated levels of
TRA-1-60 of >500 U/ml proved to have a significantly poorer recurrence-free
survival probability (P=.015 in logrank test). Six out of the 17 patients with
recurrence (35.3%) and five out of the 46 patients (10.9%) without recurrence had
elevated levels of TRA-1-60 of >500 U/ml.
Figure 1. Recurrence-free survival probability in 52 patients
with a TRA-1-60 of <500 U/ml compared to 11 patients with
a TRA-1-60 of >500 U/ml (X2 5.9; P=.015)
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Figure 1 shows the Kaplan-Meier curves for the 52 patients with a TRA-1-60 of
<500 U/ml, compared to the 11 patients with a TRA-1-60 of >500 U/ml.
However, in the multivariate comparison by means of Cox regression analysis, no
independent association was found between a TRA-1-60 of >500 U/ml and
recurrence (Hazard Ratio 2.5, 95% Confidence Interval 0.5-13.1).
Table 3 shows the proportion of elevated tumor markers in the sera of the 42
patients who developed a recurrence. Tumor marker levels were determined in the
first available serum sample, which was obtained before or less than ten days
after orchidectomy (I; n=17) and in the samples obtained one month before
CT-confirmed recurrence (II; n=42) and at the time of CT-confirmed recurrence
(III; n=42).
Table 3. Elevated tumor markers in patients with recurrence
I II III
(n=17) (n=42) (n=42)
Tumor marker positive No. % No. % No. %
TRA-1-60 10 58.8 21 50.0 24 57.1
AFP 10 58.8 8 19.0 14 33.3
hCG 5 29.4 11 26.2 19 45.2
AFP and/or hCG 10 58.8 18 42.9 26 61.9
AFP a/o hCG a/o TRA-1-60 13 76.5 28 66.7 35 83.3
I, at the time of unilateral orchidectomy; II, one month before recurrence; III, at the time
of recurrence.
In the first serum sample, ten out of the 17 patients had an elevated level of
TRA-1-60 (58.8%), ten patients had an elevated level of AFP (58.8%) and five
patients had an elevated level of hCG (29.4%). Ten patients had an elevated level
of AFP and/or hCG (58.8%), while 13 patients had elevated levels of AFP and/or
hCG and/or TRA-1-60 (76.5%). Three of the TRA-1-60 positive patients were
negative for the conventional tumor markers.
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One month before recurrence, 21 patients already had elevated levels of
TRA-1-60 (50.0%), whereas only 8 patients had elevated levels of AFP (19.0%)
and 11 patients had elevated levels of hCG (26.2%). Ten of the 21 TRA-1-60
positive patients were negative for both AFP and hCG. At the time of
CT-confirmed recurrence, 24 out of the 42 patients had an elevated level of TRA-
1-60 (57.1%), while 26 patients (61.9%) had elevated levels of AFP and/or hCG.
Nine out of the 24 patients with elevated levels of TRA-1-60 were negative for
both AFP and hCG. TRA-1-60 levels were elevated more often one month before
recurrence and at the time of recurrence than the conventional tumor markers
AFP and hCG. During polychemotherapy treatment all the elevated tumor
markers normalised.
DISCUSSION
AFP and hCG are currently in routine use for the diagnosis, staging and follow-
up of patients with NSTGCT. AFP is produced by yolk sac tumor components
and undifferentiated embryonal carcinoma cells,26 as well as by immature or
mature teratoma.27 HCG staining is present in choriocarcinoma and syncytio-
trophoblastic giant cells,26 but also in undifferentiated mononuclear embryonal
carcinoma cells.9 Lactate dehydrogenase (LDH) has been suggested as a potential
marker, but it only appears to be reliable in bulky disease. LDH rarely provides
additional information to that of serum hCG or AFP, either during therapy or
monitoring.28 Carcinoembryonic antigen (CEA) offers some advantage in that it is
elevated in the undifferentiated NSTGCT consisting of mature teratoma.29 In 80%
of the NSTGCTs, at least one of these serum tumor markers is increased.9
Nevertheless, conventional tumor markers are liable to fail in a substantial
number of patients because NSTGCTs generally contain various histological
components and cell types that differ in their ability to synthesize one or more
markers. Embryonal carcinoma is the most prevalent histological component in
NSTGCT; about 70% contain this component.30 Because the TRA-1-60 antigen is
released into the serum of patients with embryonal carcinoma-positive NSTGCT,
it is an important potential tumor marker.
TRA-1-60 was measured in 100 healthy male controls, age-matched to the tumor
population. The upper normal reference value for TRA-1-60 was calculated and
established at 230 U/ml.
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In a former publication, we described the histology of the primary tumors in this
group of patients with clinical stage I NSTGCT: 132 out of the 154 primary
tumors (85.7%) were embryonal carcinoma-positive.14 In the present study, serum
samples were available at the time of orchidectomy in 65 out of these 154
patients; 56 (86.1%) of the primary tumors in these patients contained an
embryonal carcinoma component, while 30 out of these 56 patients (53.6%) had
elevated levels of TRA-1-60 in the initial serum sample. However, four of the
patients with elevated levels of TRA-1-60 did not have an embryonal carcinoma
component in the primary tumor. It is possible that an embryonal carcinoma
element in the primary tumor was overlooked during histological examination.
The metabolic clearance rate is expressed by the half-life time of a serum tumor
marker. Several authors have proposed that the rate at which the serum tumor
marker levels decrease during or after treatment could have prognostic
significance.2,6,7,31,32 If any marker-producing tissue remains in situ, the levels can
be expected to decrease more slowly because the markers would continue to be
released into the circulation.8,25,33 For the calculation of the T½ of TRA-1-60, the
serum samples of five patients without recurrence who had TRA-1-60 levels of
>850 U/ml in the initial serum sample were used. Mean T½ was 9.5 days (range
8.5-10.5 days). The T½ of TRA-1-60 is longer than the half-life time of six days
for AFP and of two days for hCG. TRA-1-60 may be at a slight disadvantage
because of this. However, the interval between tumor marker determination and
orchidectomy was usually more than one week. Therefore it can be expected that
any increase or decline in TRA-1-60 levels would have been noted.
Marrink et al. found that TRA-1-60 was elevated more often (76%) than AFP
(57%) or hCG (38%) in patients with disseminated NSTGCT and embryonal
carcinoma in the primary tumor.13 They described that in 10 out of their 15
patients in whom the AFP and hCG levels were both within the normal range, the
TRA-1-60 level was elevated. Therefore, it was the only detectable serum tumor
marker released by the embryonal carcinoma cells. Our study population consisted
of patients with clinical stage I NSTGCT only. In the patients with recurrence,
TRA-1-60 was the only detectable serum tumor marker in three out of the 17
patients at the time of orchidectomy (17.6%). One month before recurrence, it
was the only elevated marker in ten out of the 42 patients (23.8%); at the time of
recurrence, it was the only elevated serum tumor marker in nine out of the 42
patients (21.4%). Therefore, TRA-1-60 proved to be of additional
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value to AFP and hCG in the follow-up of patients with clinical stage I NSTGCT.
Discordance in the behaviour of AFP and hCG has been described by other
investigators5,34-36 and has also been reviewed.37 This discordance presumably
reflects irradication of the marker-producing portion of the tumor cell population
with survival and recurrence of another portion.38 TRA-1-60 also seems to
display discordant behaviour: in this study, elevated values of TRA-1-60 were
found in the initial serum samples of ten out of the 17 patients who developed
recurrence. However, at the time of recurrence only seven of these patients had
elevated TRA-1-60 levels. The opposite was observed in four patients who had
normal serum TRA-1-60 levels in the first serum sample but elevated levels at the
time of recurrence. Although the TRA-1-60 levels generally follow the AFP/hCG
curves, the three markers sometimes diverge during follow-up, which provides
synergistic information for the management of patients with clinical stage I
NSTGCT.13
Other studies have shown that the incidence and perhaps the level of tumor
markers have prognostic significance.37,39,40 In our population, no significant
differences in recurrence-free survival were found in the initial tumormarker
levels of AFP, hCG and TRA-1-60 at cut-off point of 230 U/ml between the
patients with and those without recurrence. Only the patients who had elevated
levels of TRA-1-60 of more than 500 U/ml had a significantly poorer recurrence-
free survival probability (P=.015). Sensitivity, specificity and predictive values of
TRA-1-60 in the initial serum samples were similar to those of AFP and hCG.
If, on the basis of clinical, biochemical and pathological criteria, patients at high
risk of developing metastases could be identified prospectively at the time of
orchidectomy, then consideration could be given to administering immediate
adjuvant treatment with chemotherapy.3,41,42 We have reported previously on the
wait-and-see policy for patients with clinical stage I NSTGCT.14 In multivariate
logistic regression analyses, recurrence was found to be related to the presence of
vascular invasion, embryonal carcinoma, an elevated preoperative hCG level and
the absence of mature teratoma. Only vascular invasion was an independent
unfavourable prognostic risk factor for developing recurrence. On the basis of
these data, the question arises as to whether a combination of an elevated level of
TRA-1-60 of >500 U/ml and vascular invasion of the primary tumor are
predictive of recurrence. In our 17 patients with recurrence, five (29.4%) had
vascular invasion and an elevated level of TRA-1-60 of >500 U/ml. In the 46
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patients without recurrence, there were two patients who had both characteristics
(4.3%). Thus, 5 (71.4%) out of the seven patients with both characteristics
developed recurrence. Compared to the patients without elevated tumor markers
and without vascular invasion, all the patients with a combination of an elevated
level of one of the tumor markers at the time of orchidectomy and vascular
invasion, had a significantly poorer recurrence-free survival probability
(Table 4). This was valid for univariate as well as for multivariate comparison.
However, these results were obtained from a group of 63 patients with a
relatively small number of recurrences (n=17) and should therefore be
interpretated with caution. If additional studies of a larger number of patients
confirm these results, it may be justified to offer adjuvant treatment to patients
with a clinical stage I NSTGCT who have a combination of vascular invasion of
the primary tumor and an elevated level of one of the tumor markers AFP, hCG
or TRA-1-60. However, the administration of adjuvant polychemotherapy to all of
our patients with these characteristics would have meant the overtreatment of 2
out of the 7 patients (28.6%).
Table 4. Differences in recurrence-free survival probability
of patients with an elevated tumor marker and vascular invasion
(vasc), compared to patients without these characteristics
Univariate Multivariate
P P
AFP+ and vasc+ .002 .016
hCG+ and vasc+ .002 .010
TRA-1-60+ and vasc+ .007 .039
TRA-1-60 >500 U/ml and vasc+ .001 .006
These data indicate that the TRA-1-60 antigen, as a serum tumor marker in the
follow-up of patients with clinical stage I NSTGCT, provides useful additional
information. With the aid of TRA-1-60 we may be able to detect recurrences
earlier, especially in patients who are negative for both AFP and hCG. The TRA-
1-60 level in the initial serum samples taken at the time of orchidectomy is
61
TRA-1-60 in Stage I NSTGCT
not an independent risk factor for recurrence. However, univariate comparison
showed that TRA-1-60 elevation of more than 500 U/ml was an unfavourable
prognostic factor. If confirmed in other studies, it might be feasible to add
TRA-1-60 assays to the follow-up evaluation schedules of patients with NSTGCT.
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ABSTRACT
Venous access ports (VAPs) can be used to administer polychemotherapy to
patients with malignancies. The purpose of this study was to evaluate
perioperative and late complications related to VAP implantations and to analyse
factors that may predict the development of complications. During the period
1983 to 1994, 135 VAPs were implanted in 132 patients with disseminated
testicular tumors. In a retrospective study, the perioperative and late
complications were recorded in this homogeneous patient group. Multivariate
analysis was performed to detect factors that may predict the development of
complications. The median age of the patients was 28 (range 16-55) years.
Perioperative complications were recorded in five patients (3.7%): pneumothorax
in two (1.5%), blood loss in two (1.5%) and mediastinal bleeding in one (0.7%).
The ports remained in situ for a total of 55247 days, median 413 (range 7-1607)
days. In 31 patients (23%), 42 late complications developed (31%): system
obstruction in 13 (9.6%), thrombosis in 11 (8.1%), infection in six (4.4%),
catheter defect in six (4.4%), extravasation in four (3.0%) and local skin necrosis
in two (1.5%). Late complications were significantly more common in the patients
who had received chemotherapy prior to VAP implantation (P<.001). Univariate
analysis showed that there were significantly more complications after VAP
implantation under local anesthesia than under general anesthesia (P<.05).
Polychemotherapy could be administered in an adequate manner using a VAP.
Complications occurred in 26.7% of a homogeneous group of patients who
received a VAP implantation for polychemotherapy for disseminated testicular
cancer. Chemotherapy treatment prior to VAP implantation was the only
independent risk factor for late complications.
INTRODUCTION
At the end of the 1970s, cisplatin became available for use in polychemotherapy
combinations to treat patients with disseminated testicular cancer. This
considerably improved the prognosis of these patients.1 In the most frequently
used chemotherapy combinations, PVB (Platinum, Vinblastine and Bleomycin)1
and BEP (Bleomycin, Etoposide and Platinum),2 cisplatin is administered for five
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consecutive days. To prevent nephrotoxicity induction by cisplatin, it is necessary
to perform pre- and post-hydration. In addition, blood samples have to be
obtained frequently to monitor the efficacy and toxicity of the polychemotherapy.
Vena puncture and long-term peripheral infusions may damage the venous intima.
Sclerosing effects of cytostatics often cause chemical thrombophlebitis, while
intima damage and thrombophlebitis lead to secondary thrombosis.3 Consequently,
it is more difficult to insert a peripheral infusion and the risk of extravasation
increases.4
Since the introduction of chemotherapy, a great deal of attention has been paid to
achieve an adequate means of venous access that is suitable for long-term use.5
Based on the poor experience with peripheral access infusions, at the University
Hospital Groningen, the Netherlands, initially arteriovenous (AV) shunts were
used for this purpose. Although these shunts were used widely for haemodialysis,
they proved to be unsuitable for the long-term administration of chemotherapy to
patients with disseminated testicular tumors. Even though this is a young
otherwise healthy patient population a high incidence of phlebosclerosis and
thrombosis was noted.3 In 1982, the venous access port (VAP) was introduced for
administering chemotherapy. A reservoir was implanted subcutaneously and atta-
ched to a catheter that provided access to the central blood vessels.6 This system,
which was fully implanted under the skin, carried a low risk of infection and
imposed little or no restriction to the patient in the daily activities.6-8
Because of the disappointing experiences with peripheral access infusions and AV
shunts, at the University Hospital Groningen, from 1983 the VAP was used for
the administration of cisplatin-based polychemotherapy to patients with
disseminated testicular cancer.9 This report describes more than ten years of expe-
rience with the VAP in this homogeneous patient group. The occurrence of
perioperative and late complications related to the VAP were studied and special
attention was paid to factors that may predict the development of late
complications.
PATIENTS AND METHODS
In the period from January 1983 to January 1994, 135 VAPs (Strato/Infusaid Inc.
Norwood, MA, USA) were implanted in 132 patients with disseminated testicular
cancer at the University Hospital Groningen. The VAPs consisted of a
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polysulphonate port with a 8 french radiopaque silicon catheter I.D. 1.0 mm x
O.D. 2.5 mm. Clinical staging was conducted according to Peckham et al.10 The
tumors were classified according to the nomenclature of the World Health
Organisation.11 In principle, the VAP was implanted before polychemotherapy
treatment was started. Prior to 1989, patients with a disseminated testicular tumor
underwent a staging laparotomy to determine the extent of retroperitoneal
metastases.12 During the operation, the VAP was also implanted. Nowadays
clinical staging is performed with CT scanning of the abdomen and thorax and
the VAP is implanted exclusively under local anesthesia.
The heparin-filled VAP was inserted into a small subcutaneous pocket via a
transverse skin incision 8 cm above the left areola mamma. The port was not
secured in the pocket. Subsequently, a catheter was introduced into the left
subclavian vein according to the Seldinger technique. The position of the tip of
the catheter was monitored with X-ray screening. At this stage, the patency of the
VAP was also checked. After implantation, a chest X-ray was taken to exclude a
pneumothorax and determine the exact position of the catheter. If it was not
possible to apply the Seldinger technique for technical reasons, venotomy of the
cephalic vein or external jugular vein was performed and catheter-placement
followed.
The use of the VAP was standardized according to protocol. Before starting
chemotherapy, the intravascular position of the catheter was verified by taking a
blood sample via the VAP. If it was not possible to obtain a blood sample,
magnesium sulphate was injected into the port to exclude extravasation or
thrombosis.13 At the start of a treatment cycle, the port was punctured once only
with an L-shaped Huber point needle (B. Braun Medical BV, Melsungen,
Germany) and the area was covered with a sterile dressing until the total infusion
process was completed. After completion of the treatment cycle, the system was
flushed with saline solution and filled with heparin. The VAP remained in situ for
up to one year after polychemotherapy had been completed. If there was no tumor
recurrence in this period, the VAP was removed.
Perioperative and late complication of the VAP were evaluated in retrospect. The
following peroperative complications were studied: pneumothorax, excessive
blood loss during puncture of the subclavian vein, mediastinal haematoma and
damage to adjacent nerves.14-17 The following late complications were studied:
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thrombosis, local and systemic infection, system obstruction, extravasation, local
skin necrosis and catheter defects, i.e. fracture and rupture.15,18-20 Table 1 presents
an overview of the definitions used for these late complications.
Table 1. Definitions
Thrombosis
Thrombosis of the subclavian vein and/or axillary vein*
Infection
- Local: erythema of the skin and pain at the port site, with or without
bacteriological confirmation
- Systemic: fever, with or without bacteriological confirmation, which
disappeared after the catheter had been removed
System obstruction
Obstruction in the reservoir and/or catheter, without thrombosis
Extravasation
Escape of cytostatics from the blood vessels
Local skin necrosis
Necrosis of the skin at the port site, with or without perforation
Catheter defect
- Catheter fracture: a segment of the catheter-part of the VAP broke off
- Catheter rupture: leakage of cytostatics through a rupture in the catheter-part
* Diagnosed clinically and confirmed with Doppler
Late complications were evaluated in relation to the following patient
characteristics: age, clinical stage of the testicular tumor, histology of the primary
tumor, chemotherapy prior to implantation, increased tumor markers AFP and/or
hCG before treatment, bone marrow depression during chemotherapy and a
history of thrombosis. Late complications were also evaluated in relation to the
following VAP characteristics: implantation side, the vein that was used, the
position of the catheter tip, the number of attempts to implant the VAP,
complications during implantation of the VAP, local anesthesia versus general
anesthesia and the operator; surgeon versus surgical resident. The number of
complications is expressed per 1000 patient days, i.e. the number of
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days that the VAP was in situ.21 Follow-up continued until the VAP was removed
or the patient died.
Statistical analysis
Differences in patient characteristics and VAP characteristics between the two
subgroups of patients with and without complications were analysed as continuous
variables by means of Student’s t test (all complication together) or the Mann-
Whitney test (each complication separately). The Chi-square test was used for
categorical variables and Fisher’s exact test for small numbers. Multivariate
logistic regression analysis was performed to evaluate independent associations
between the various prognostic factors and the occurrence of complications.
Possible prognostic factors were chosen on a theoretical basis and on the basis of
the univariate analyses.22 The following prognostic factors were included in the
multivariate analyses: age, clinical stage IV (yes versus no),
pre-VAP chemotherapy (yes versus no), number of implantation attempts
(>1 versus 1) and the type of anesthesia (local versus general). The presence of a
late complication was the dependent variable with the absence of a complication
as reference category. In the multivariate analyses, patients with multiple
complications were considered as separate cases for each complication. The level
of statistical significance was set at P<.05. Odds ratios were considered to be
significant if the 95% confidence interval did not contain the value 1. Statistical
analyses were conducted using the SPSS-PC+ statistical software package (SPSS
Inc. Chicago, III., USA).
RESULTS
A total of 135 VAPs were implanted in 132 patients who underwent cisplatin-
based chemotherapy for disseminated testicular cancer. The median age was 28
(range 16-55 years, SD 7.8) years. In 125 patients the primary tumor was a
nonseminomatous testicular tumor (94.7%); the seven remaining patients had a
seminoma (5.3%). At the time of VAP implantation, 59 patients had stage II
disease (44.7%), 14 had stage III (10.6%) and 58 had stage IV (43.9%). In one
patient the stage was unknown (0.8%). It was necessary to start chemotherapy
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immediately in 13 patients (9.8%) due to poor clinical condition and/or extensive
metastatic disease. In these 13 cases, the VAP was implanted at the first
opportunity, usually directly after the first treatment cycle. The median number of
polychemotherapy cycles was four (range 1-14).
The techniques used to implant the 135 VAPs were the Seldinger method, i.e.
subclavian vein puncture (n=126, 93.3%), venotomy of the cephalic vein (n=8,
5.9%) and venotomy of the right jugular vein (n=1, 0.8%). Implantation was
conducted under general anesthesia during a staging laparotomy12 in 103 cases
(76.3%) and under local anesthesia in 32 cases (23.7%); 121 VAPs were
implanted on the left and 14 on the right (10.4%). In 19 patients, more than one
attempt was made to position the catheter correctly. The tip of the catheter was
located in the superior vena cava in 126 cases (93.3%), in the right atrium in five
cases (3.7%) and in the internal jugular vein in four cases (3.0%).
Perioperative complications
Perioperative complications occurred in five of the 135 VAPs (3.7%). These
comprised a pneumothorax in two patients (1.5%) which necessitated thorax
drainage; excessive blood loss in two patients (1.5%) which could be treated
conservatively and mediastinal bleeding in one patient (0.8%) in whom the VAP
implantation procedure had to be discontinued.
Late complications
The 135 VAPs were in situ for a total of 55247 days and there were 42 (31.1%)
complications in 31 patients. Eight patients had two complications and one patient
had four complications. The total number of complications corresponds with 0.76
complication episodes per 1000 patient days. The median implantation time of the
VAPs was 413 (range 7-1607) days. In four VAPs, all without complications, the
precise number of days in situ was unknown. The incidence of late complications
was therefore calculated for 131 VAPs. In the subgroup of VAPs with one com-
plication, the median number of days in situ was 308 (range 55-1055) days, while
in the subgroup with more than one complication, it was 265 (range 78-894) days.
There were no complications in 101 patients (76.5%). During follow-up, 13
patients died (10.2%); mortality was not related to VAP
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complications. Table 2 lists the late complications.
Table 2. Incidence and interval until late complications
occurred in 135 VAPs
Complication No. of patients Incidence1 No. of days (range)2
System obstrucion 13 (9.6%) 0.24 40 (5-601)
Thrombosis 11 (8.1%) 0.20 33 (2-518)
Infection 6 (4.4%) 0.11 75 (39-430)
Extravasation 4 (3.0%) 0.06 72 (41-85)
Local skin necrosis 2 (1.5%) 0.04 197 (60-333)
Catheter defect 6 (4.4%) 0.11 363 (55-1241)
1 Per 1000 patient days; 2 Median number of days in situ until complication occurred.
System obstruction was the most frequent complication. The obstruction could be
alleviated by injecting the VAP with saline solution, heparin or urokinase.
Thrombosis was diagnosed clinically (redness, swelling and pain) and was
confirmed with Doppler scanning. It occurred in 11 cases: six in the subclavian
vein, four in the axillary vein and in one in the brachiocephalic vein. The port
was removed for this reason in one patient, four patients received a thrombolytic
agent and six patients were treated expectatively. All patients recovered fully
from this thrombosis, which was confirmed with Doppler scanning.
Infection: six cases of infection occurred in five patients. Infection was local in
two patients. There were four cases of systemic infection in three patients. All
these patients received intravenously antibiotic therapy. Two of the three VAPs
had to be removed because of continued systemic infection.
Extravasation occurred in four patients and comprised subcutaneous leakage of
the cytostatics at the port site. Three of these patients were treated conservatively;
the VAP was removed in one patient.
Local skin necrosis developed in two patients at the port site. In both cases, the
VAP had to be removed.
Catheter defects: these mechanical complications occurred in six cases (five
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fractures and one rupture). Two of the five fractures were detected on routine
chest X-ray 256 and 454 days after implantation, respectively. The remaining
three fractures were detected during VAP removal after 350, 376 and 1241 days,
respectively. The broken catheter segments migrated to the pulmonary artery in
four of the five cases and to the right atrium in the remaining patient. In all cases
they could be removed by catheterisation under local anesthesia via the femoral
vein.19 The catheter ruptured in one patient after 55 days, replacement of the VAP
was performed.
The relationship between patient characteristics and late complications was
analysed. Of the 13 patients who had received chemotherapy prior to VAP
implantation, 9 (69.2%) developed at least one late complication. This was
significantly different from the 33 complications (27.7%) that occurred in the 119
patients who started chemotherapy after VAP implantation (P<.001). The
difference was mainly due to thrombosis (n=4) and system obstruction (n=4) in
the pre-chemotherapy implantation group versus seven thromboses and nine
system obstructions in the post-chemotherapy implantation group (P<.05). No
significant relationships were found between late complications and: age, clinical
stage, histology of the primary tumor, increased tumor markers, bone marrow
depression and a history of thrombosis (data not shown).
Analysis was also made of the relationship between the implantation procedure of
the VAP and late complications. In the 32 VAPs that were implanted under local
anesthesia, 12 patients had one or more late complications (37.5%). This differed
significantly from the 19 (18.4%) complications that occurred in the 103
implanted VAPs under general anesthesia (P<.05). This difference was mainly due
to thrombosis: four cases in the 32 VAP implants conducted under local
anesthesia versus seven cases in the 103 implants conducted under general
anesthesia. No significant relationships were found between late complications
and: implantation side, implantation vein, position of the catheter tip, number of
attempts to position the catheter, complications during implantation and the
operator (data not shown).
Multiple logistic regression analysis was performed to examine the relationship
between each patient characteristic or VAP characteristic and the occurrence of
late complications, adjusted for the remaining potential characteristics (Table 3).
Chemotherapy treatment prior to VAP implantation was found to be the only
independent risk factor for late complications (Odds Ratio 7.4; 95% Confidence
Interval 1.8-30.4).
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Table 3. Multiple logistic regression analysis: Odds Ratios
for the occurrence of late complications (n=135)*
Independent variable Odds Ratio 95% CI
Age 1.0 0.9 - 1.1
Stage IV (yes versus no) 1.2 0.5 - 2.9
Pre-VAP chemotherapy (yes versus no) 7.4 1.8 - 30.4
Number of attempts (>1 versus 1) 2.1 0.7 - 6.4
Anesthesia (local versus general) 1.5 0.5 - 4.5
* No complication was the reference category
DISCUSSION
Aubaniac was the first to describe the use of a central catheter in 1952.23 It was
mainly used for parenteral feeding.24 In 1973, Broviac introduced the tunnelled
silicone rubber catheter,25 which was adapted later by Hickman and Ivey.26,27
These central venous catheters carried the disadvantages of an increased risk of
infection and inconvenience for the patient.28-30 Since the introduction of the VAP
in the eighties, various authors have evaluated its advantages over traditional
external catheters.7,31 In a prospective randomized study, Mueller et al. did not
find any significant difference in the incidence of infection, thrombosis or
mechanical complications between the VAP and the external catheter.31 Carde
also performed a prospective randomized study and found that in patients with a
solid tumor who had been receiving treatment with intravenous chemotherapy for
longer than six months, the totally implantable systems were more reliable, safer
and better tolerated than the traditional external catheters.7 The totally implantable
systems are cosmetically superior and more easily accepted by the patients than
the external catheters.6 Therefore, the VAP usually takes preference as access
system for chemotherapy.
This is the first study to describe the use of the VAP on a large homogeneous
patient group and to use it exclusively for administering cisplatin-based
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chemotherapy. Other authors described complications that occurred with the VAP
in patients with diverse malignancies and non-malignancies.15,18,32,33 In a great
number of these studies, the VAP was not only used for administering
chemotherapy, but also for other purposes, such as parenteral feeding and/or
blood transfusions.
In this study, two types of complications were distinguished: perioperative and
late complications. The number of complications in this homogeneous patient
group did not differ essentially from the percentages reported in the literature for
various patient groups. The number of perioperative complications consisting of
pneumothorax and blood loos was described in percentages of 1.7 to 8.0
%.14,15,34,35 Late complications consisting of system obstruction, thrombosis,
infections, extravasation and local skin necrosis was described in percentages of
0.0 to 55.5%.14,15,21,31-43 Only the percentage of catheter defects (4.4%) was larger
than in the other studies (0.4%-1.4%).31,32,33,39 Possible explanations for this are:
too medial positioning which caused friction of the catheter between the clavicle
and the first rib (’pinch off sign’) and/or the long duration in situ time.44,45
The incidence of complications per 1000 patient days was also in agreement with
the incidences reported in other studies (Table 4). The VAPs in this study
remained in situ for much longer than they did in other studies and were
consequently at risk for a longer period, because at the University Hospital
Groningen, it was decided to leave the VAPs in situ for up to one year after the
completion of treatment so that if recurrent disease was diagnosed, chemotherapy
treatment could be continued via the VAP. However, leaving the VAP in situ for
a longer period increased the risk of catheter defects. Therefore, it may be worth
considering earlier removal.
In 13 patients, chemotherapy had to be started immediately because of extensive
metastasic disease and/or poor clinical condition. Both univariate and multivariate
analyses showed that a significantly greater proportion of these patients developed
late complications (P<.001; Odds Ratio 7.4). These were mainly venous
thrombosis and system obstruction. Donohue and Rowland reported that
morbidity, unfortunately not further specified, was higher in the patients who
underwent laparotomy after chemotherapy for a testicular tumor, than in those
who had not received chemotherapy.46 Their explanation was that the ensuing
decrease in pulmonary, renal and nutritive reserves may have caused this increase
in morbidity.
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Table 4. Complication incidence expressed as the number of
episodes per 1000 patient days
Lokich’8536 Brothers’8815 Freytes’9018 Grannan’9014 Ramirez’9332 Lemmers’96
Patients
number 92 300 128 66 176 132
age range n.d. 9-83 18-82 22-82 16-76 16-55
VAPs
number 92 329 134 66 185 135
application A B A B A C
days in situ
- median 127 257 308 152 276 413
- total 12797 116208 40628 10016 51150 55247
Complication ratio’s
thrombosis 1.20 0.13 0.02 0.20 0.10 0.20
infection 0.63 0.46 0.07 0.39 0.08 0.11
system obstr. 1.02 0.26 0.07 n.d. 0.10 0.24
extravasation 0.47 0.18 0.05 n.d. 0.14 0.06
skin necrosis n.d. 0.04 0.05 n.d. n.d. 0.04
catheter defect n.d. n.d n.d. n.d. 0.04 0.11
total 3.32 1.07 0.26 0.59 0.46 0.76
Abbrevations: A, administration of various chemotherapy combinations to patients with
various types of malignancy; B, A plus administration of parenteral feeding and blood
products to patients with various types of malignancy and non-malignancy; C,
administration of cisplatin-based polychemotherapy to patients with testicular cancer;
n.d., not described.
The patients who had received chemotherapy before VAP implantation showed a
greater number of complications, although this pre-VAP chemotherapy was
administered by peripheral access infusions. This may be due to the sclerosing
effects of cytostatics. Univariate analysis showed that there were significantly
more complications in the VAPs that had been implanted under local anesthesia
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than under general anesthesia (P<.05); these were also mainly thrombosis. A
possible explanation for this is that it was easier to puncture the subclavian vein
under general anaesthesia with positive pressure mechanical ventilation causing
vasodilatation, than under local anesthesia. However, this did not prove to be an
independent risk factor in the multivariate analysis.
Mansfield found a lower percentage of complications in catheterisations of the
subclavian vein performed by experienced physicians (10.2%) than in those
performed by inexperienced physicians (13.5%); however, this difference was not
statistically significant.35 In this study, the number of complications was not
related to the experience, surgeon versus surgical resident.
In conclusion, implantation and use of a VAP to administer polychemotherapy to
patients with disseminated testicular cancer was accompanied by a complication
rate of 26.7%. The only independent risk factor for occurrence of late
complications in this study was the administration of chemotherapy prior to VAP
implantation. Therefore, in patients with a diagnosis of disseminated testicular
cancer who are scheduled to undergo long-term polychemotherapy, the VAP must
be implanted before chemotherapy treatment is initiated.
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ABSTRACT
The objective of this study was to evaluate the resection of the retroperitoneal
residual tumor mass (RRTM) for histological examination after chemotherapy in
patients with disseminated nonseminomatous testicular germ cell tumors
(NSTGCT), with particular attention to surgical morbidity. From 1979 to 1995,
112 patients (mean age 28 years, range 16-53) with disseminated NSTGCT had
residual disease after chemotherapy for which surgical evaluation was indicated;
the histology of the residual tumor and the surgical complications were assessed.
Possible associations between the occurrence of surgical complications and the
age of the patient, size the residual tumor, operative duration, previous
laparotomy and pathological findings were evaluated. The median size of the
residual tumor was four cm (range 0-18); histological examination revealed
viable cancer in 9.0%, mature teratoma in 44.1% and necrosis/fibrosis in 44.1%
of the patients. In 3 patients (2.8%) no residual tumor mass was found at
laparotomy. There were 26 complications in 20 patients (18.0%); urinary tract
infection was the most common, occurring in nine patients (8.1%). One patient
died during the induction of anesthesia. There were no significant relationships
between the occurrence of complications and age, size of the residual tumor,
operative duration, previous laparotomy or pathological findings. The resection of
RRTM after polychemotherapy treatment for disseminated NSTGCT is a safe
surgical procedure, with low treatment morbidity, mainly consisting of urinary
tract infection. Knowledge of the potential complications may help to prevent
morbidity. However, the surgical evaluation of the ultimate effect of poly-
chemotherapy remains the gold standard.
INTRODUCTION
The initial treatment of patients with disseminated nonseminomatous testicular
germ cell tumors (NSTGCT) is cisplatin-based polychemotherapy. The previously
dismal prognosis of these patients has been improved dramatically with the
development of this effective treatment.1 However, on completion of the
remission-inducing polychemotherapy, retroperitoneal residual tumor mass
(RRTM) is still found regularly. Shrinkage of metastases may cease due to
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necrosis and fibrosis or they may persist as mature teratoma.2,3 Sometimes viable
cancer is present. All mature teratoma tissue has to be removed to prevent the
occurrence of the growing teratoma syndrome4 or the development of a secondary
malignancy in residual mature teratoma.5-7 If malignant tumor tissue is still found
to be present in the postchemotherapy resected specimen, salvage chemotherapy is
indicated. Nevertheless postchemotherapy resection of RRTM has an important
role in patients with retroperitoneal residual disease following normalisation of
tumor markers with polychemotherapy. Resection of all the residual lesions for
histopathology is necessary to evaluate the ultimate response. If no pathological
mass is visible on the postchemotherapy computed tomogram (CT scan), some
authors still advocate resection in the following situations: if a teratomatous
component was present in the primary tumor;3 if prechemotherapy retroperitoneal
lymph node metastases were larger than 30 mm;8 or if laparotomy is performed
routinely as part of the treatment policy.9
At the University Hospital Groningen, the Netherlands, laparotomy is performed
on all patients with a disseminated NSTGCT who become serum tumor marker-
negative following remission-inducing polychemotherapy and who show evidence
of retroperitoneal residual disease, or had mature teratoma in the primary tumor.
The current paper describes the experience with postchemotherapy resection of
RRTM and attention is focused on postoperative morbidity.
PATIENTS AND METHODS
In the period July 1979 to March 1995, 112 consecutive resections of RRTM
were performed at the University Hospital Groningen, the Netherlands, in patients
with disseminated NSTGCT. All patients were treated with cisplatin-based
polychemotherapy; in all cases it was the first operation after chemotherapy treat-
ment. Initial clinical staging was performed by physical examination, chest X-ray,
serum tumor markers alpha-fetoprotein (AFP) and human chorionic gonadotrophin
(hCG) levels and CT scans of the chest and abdomen.10 Until 1989, staging
laparotomy was performed in patients with disseminated NSTGCT in conjunction
with orchidectomy, to make a definite diagnosis regarding the size of the
retroperitoneal lymph node metastases. On the basis of previous analyses, it was
decided from that time onwards to perform this staging laparotomy only if radio-
logical findings were inconclusive.11 Since then
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patients have been clinically staged with CT scans of the chest and abdomen.
Patients with Stage I disease were treated according to the wait-and-see policy.12
Patients with Stage II or higher were treated with cisplatin-based
polychemotherapy: cisplatin, vinblastine and bleomycin (PVB) or bleomycin,
etoposide and cisplatin (BEP). A total of four remission-inducing courses were
administered; each course had a duration of three weeks. Up to 1982, patients
were given maintenance treatment, as was usual at that time. This policy was
changed on the basis of data that became available in the early eighties.13 After
completion of the polychemotherapy, the patients were clinically restaged with
CT scans of the chest and abdomen and monitored for serum tumor markers. If
serum tumor markers were still high or failed to decrease according to the known
serum half-life times, supplementary salvage chemotherapy was administered.
Otherwise any residual tumor was removed surgically and examined
pathologically. This treatment strategy has been described previously by Donohue
and Rowland.14
Over eighty percent of the resections of RRTM were performed by, or in the
presence of the same surgeon. In total, four surgeons were involved in the
treatment. The technique of trans-abdominal and thoraco-abdominal resection of
RRTM used at the University Hospital Groningen had been described by
Wobbes.15 Generally, partial retroperitoneal lymph node dissection was performed.
Standard preoperative procedures included subcutaneous heparin injection to
prevent thrombosis, introduction of a gastric tube to prevent stomach dilatation
and aspiration, and the introduction of a urinary catheter to monitor urine
production during the operation. The urinary catheter also ensured
collapse of the bladder and thus facilitated surgery in the pelvic area. Anesthetic
management included continuous monitoring of oxygen saturation and intermittent
arterial blood gas analysis. After induction, the FiO2 was maintained at the lowest
level possible to still allow adequate oxygenation (21-25%).16 The patients did not
receive any perioperative antibiotics. Postoperative pain medication was not
standardised. The histology of the resected residual tumor mass was compared to
that of the primary testicular tumor, using the nomenclature of the World Health
Organisation.17
Complications of postchemotherapy resection of RRTM were studied. A possible
association between the occurrence of complications and the age of the patient,
size of the residual tumor, operative duration, previous laparotomy and
pathological findings was evaluated. Differences between subgroups of patients
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with and without complications were analysed by means of the Mann-Whitney
U-test for continuous data; for categorical variables, the Chi-square test was used
or Fisher’s exact test in case of small numbers.
RESULTS
The mean age of the 112 patients was 28 (range 16-53) years; 77 of them had
undergone staging laparotomy before remission-inducing polychemotherapy was
initiated. Clinical staging at the time of diagnosis was as follows: Stage IIa, eight
patients (7.1%); Stage IIb, 38 patients (33.9%), Stage IIc, 16 patients (14.3%);
Stage III, 23 patients (20.6%); and Stage IV, 27 patients (24.1%). The median
interval between the last dose of combination chemotherapy and resection of the
RRTM was 38 (range 6-467) days. Of the 112 patients, 111 eventually underwent
surgery. One patient (0.9%) died during induction of anesthesia. He experienced
asphyxia, bradycardia and despite resuscitation efforts cardiac arrest. This patient
was excluded from the analyses. The trans-abdominal technique was used in 109
patients. In two patients who also had residual pulmonary disease, the thoraco-
abdominal approach was used, i.e. laparotomy with median sternotomy in one
patient and laparotomy with left posterolateral thoracotomy in the other patient.
The median operative duration, defined as time from incision to skin closure, was
150 (range 30-550) minutes. Median size of the residual tumor mass was four
(range 0-18) centimetres. To enable the removal of all residual tumor tissue, parti-
al resection and reconstruction of the aorta had to be performed in one patient
and nephrectomy in four other patients.
Evaluation of the response to polychemotherapy
Of the 111 patients operated on, 67 (60.4%) had a mature teratoma component in
the primary tumor. This mature teratoma component was also present in the
retroperitoneal residual tumor mass in 42 out of these 67 patients (63%), as well
as in the residual tumor in 11 out of the 44 patients (25%) who did not have
mature teratoma in the primary tumor. Thus, a total of 53 patients (47.7%) had
residual mature teratoma. Despite normalisation of the serum tumor markers,
histological examination still revealed viable cancer in 10 (9.0%) patients
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(Table 1), among whom four also had a mature teratoma component in the
residual tumor. Forty-nine patients had only residual mature teratoma in the
resected tumor tissue (44.1%). In 49 other patients (44.1%) only necrosis and/or
fibrosis was found. Although CT scans of the abdomen had identified a small
retroperitoneal residual tumor mass, in three patients (2.8%) no residual retroperi-
toneal tumor mass was found at laparotomy, therefore resection was not
performed.
Table 1. Histological composition of the retroperitoneal mass











Abbreviations: C, choriocarcinoma; E, embryonal carcinoma; I, immature teratoma;
M, mature teratoma; Y, yolk sac tumor
Complications of resection of RRTM
There were 26 complications in 20 patients (18.0%). Three patients had two
complications and one patient had four complications. Median hospitalization for
uncomplicated resection of RRTM was seven (range 4-14) days, compared to 11
(range 5-33) days in patients with complications (P=.005). Table 2 shows a list of
these complications, compared to the current literature.
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Table 2. Complications of retroperitoneal surgery
Complication Skinner’8218 Moul’8919 Jewett’9120 Wahle’9421 Baniel’9522 Gels’96
No. patients 149* 148* 100* 40** 603** 112***
Wound infection 3 4 7 1 29 1
Wound dehiscence 2 2 2 1 - 1
Paralytic ileus < 6 days - 0 2 - 1 3
Paralytic ileus > 6 days - 3 1 - 13 0
Ileus; laparotomy 3 8 6 2 0 0
Chylous ascites - 1 2 - 12 1
Lymphocele 1 2 3 2 10 2
Pancreatitis - 1 - - 6 0
Gastro-intest. bleeding - - 3 - 3 0
RP bleeding; laparotomy - - 1 - 1 1
RP/abdominal abscess 1 1 - - - 0
RP/abdominal hematoma - 1 1 - 1 1
Colon necrosis - - - - 1 0
Ureteral injury - 1 - - 6 0
Ureteral stricture/obstruction - - 5 - - 0
Urinary tract infection - - 1 - 5 9
Ischemic damage kidney - 2 4 - 1 0
Renovasc. hypertension 1 2 1 - 2 0
Atelectasis/Pneumonia 2 2 4 - 34 0
ARDS - 1 - - 6 0
Prolonged ventilation - - - - 5 2
Pulmonary embolism - - - - 1 0
Femoral neuropathy - - - 1 3 2
Other neural injury - - - - 4 0
Other complications 7 19 6 - - 3
Total complications 20 50 49 7 144 26
in number of patients 19 45 35 6 125 20
(13.0%) (30.4%) (35.0%) (15.0%) (20.7%) (18.0%)
Mortality post-operative 2 0 0 0 5 0
(1.3%) (0%) (0%) (0%) (0.8%) (0%)
Mortality anesthesia - - - - - 1
(0.9%)
* pre- and postchemotherapy retroperitoneal lymph node dissection (RPLND)/resection of
residual retroperitoneal tumor mass (rRRTM); ** postchemotherapy RPLND/rRRTM;
*** postchemotherapy rRRTM; - not described; RP, retroperitoneal; ARDS, Adult
Respiratory Distress Syndrome
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Wound infection. This complication occurred in only one patient, who also
developed wound dehiscence four days after the infection.
Gastrointestinal complications. Ileus of less than six days duration was noted in
three patients and was of a paralytic nature. All recovered after conservative
treatment. Significant ileus for six days or longer postoperatively was not
observed.
Lymphatic complications. Complications related to the lymphatic system were
observed in 3 patients. Chylous ascites appeared in one patient after nine days.
This patient responded well to conservative treatment with a low fat diet and
diuretics. In two patients lymphocele occurred; both were diagnosed within one
month after surgery. In one patient the lymphocele was aspirated under
ultrasonographic guidance and did not recur. In the other patient, the lymphocele
appeared to be infected. This necessitated puncture under ultrasonographic
guidance and drainage for 9 days.
Retroperitoneal bleeding or hematoma. A significant decrease in the hemoglobin
level was noted in one patient, with the clinical suspicion of retroperitoneal
bleeding. This required relaparotomy. However, except for some oozing, no
significant source of bleeding was found. One patient on anticoagulation therapy
for pulmonary embolism (before surgery) complained about abdominal pain after
12 days. Ultrasonographic imaging showed a solid mass in the retroperitoneum,
which after puncture turned out to be a hematoma. This patient responded well to
conservative treatment.
Urinary tract complications. Urinary tract infection was the most common
complication in this study: nine patients (8.1%). These patients were treated
successfully with antibiotics.
Pulmonary complications. Two patients needed prolonged postoperative
ventilation because of inappropriate oxygenation for two and five days,
respectively. Respiratory failure due to pneumonia, the adult respiratory distress
syndrome or pulmonary embolism was not observed.
Neurological complications. Femoral nerve neuropathy occurred in two patients.
Both patients recovered early in the convalescent phase.
Other complications. Two patients developed moderately severe postoperative
diarrhoea of undetermined etiology. One patient developed a bacterial infection in
both eyes, due to insufficient care during anesthesia. No significant differences
were found in the age of the patient, size of residual tumor, operative duration,





Surgical resection is widely accepted as the treatment of choice for retroperitoneal
residual masses after polychemotherapy for metastatic NSTGCT.1 Resection
enables histological diagnosis of the residual mass, which may be
purely benign with necrotic and/or fibrotic remnants only, or may contain mature
teratoma elements or viable cancer. Resection of masses containing necrosis or
fibrosis only is assumed to be of no therapeutic benefit and is usually not
followed by additional treatment. Resection of mature teratoma is considered to
be beneficial as it prevents growth of potentially malignant cells.8 If resection is
not performed, masses that contain mature teratoma may start to grow during
follow-up (growing teratoma syndrome).4 Resection may then be more
complicated than it would have been shortly after the completion of
chemotherapy. Finally, leaving masses with residual viable cancer unresected
involves a serious risk. The presence of viable cancer in the residual mass directs
the decision to administer additional chemotherapy.14
In this series, histological examination revealed viable cancer in only ten out of
the 111 patients (9.0%); four of these patients also had a mature teratoma
component in the residual tumor. Mature teratoma without viable cancer was
found in 49 patients (44.1%). In 49 other patients only necrosis and/or fibrosis
was found (44.1%) and in three patients resection was not performed because no
residual tumor mass was found at laparotomy. The incidence of necrotic debris,
mature teratoma, or viable cancer varies in different studies. In general, pathology
reports revealed necrosis and/or fibrosis in about 40%, teratoma in another 40%
and viable cancer in the remaining 20%.2
As histology determines the need for of resection, attempts have been made to
predict the postchemotherapy histology.23-25 Steyerberg found that predictors of
necrosis were the absence of teratoma elements in the primary tumor,
prechemotherapy normal AFP, normal hCG and elevated lactate dehydrogenase
(LDH) levels, a small prechemotherapy or postchemotherapy mass and large
shrinkage of the mass during chemotherapy. However, mature teratoma cannot
easily be distinguished from viable cancer. The value of Magnetic Resonance
Imaging (MRI) in the treatment evaluation of retroperitoneal lymph node
metastases from NSTGCT was studied by Hogeboom et al.26 They found that
MRI was unable to predict the outcome of chemotherapy treatment.
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Recently, Stephens et al have described a study to assess the ability of Positron
Emission Tomography (PET-scanning) to differentiate between residual
radiographic abnormalities in postchemotherapy NSTGCT patients. They found
that PET could not differentiate necrosis/fibrosis from teratoma, but it could
differentiate viable cancer from residual necrosis/fibrosis or teratoma.27 Until now,
the only procedure which gives optimal and accurate information regarding the
histology of a residual retroperitoneal mass is pathological investigation of
resected specimens obtained by surgery. However, the great advantage of surgery
must be weighed against the disadvantages, i.e. complications.
Postoperative complications after resection of RRTM can be divided into two
groups: general complications of the type that can develop after any laparotomy
and specific complications of retroperitoneal lymph node dissection (RPLND).
General complications include: postoperative haemorrhage, pneumonia,
thromboembolism, urinary infection and disturbed wound healing. Although
chylous ascites and lymphocele cannot be regarded as specific complications of
RPLND, they are nevertheless conditions caused by damage to the retro-
peritoneal lymph node plexus. Infertility due to the loss of emission as a result of
resection of the sympathetic nerves that traverse the area of resection, is a specific
and common complication in patients who undergo full bilateral
postchemotherapy RPLND. Less frequently it occurs in patients who undergo
resection of RRTM after polychemotherapy. This complication has recently been
assessed specificially by Van Basten et al.28 They found that after resection of
RRTM the prevalence rate of absence of ejaculation was 25.9%. The volume of
the retroperitoneal residual masses was higher (95 cm3) in the patients with absen-
ce of ejaculation than in those whithout ejaculatory dysfunction (40 cm3). The
absence of ejaculation was reported significantly more often in patients with right
paracaval/inter aorta-caval located tumor (34.5%) than in those with left para-
aortal located tumor (16.7%).
Overall, the number of complications did not differ essentially from the numbers
reported in the recent literature (Table 2). It should be realized that the acute and
long-term toxicity of chemotherapy can give rise to complications during surgical
procedures. For instance bleomycin produces acute interstitial pneumonia and
chronic fibrotic changes in the lung. Its use in standard testis cancer protocols
places all such patients at risk for pulmonary insufficiency after long periods of
anesthesia.16 However, we did not observe an increased number of pulmonary
complications, which may have been due to the low level of FiO2 during
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anesthesia. Although most authors did not report urinary tract infections, this
complication occurred fairly frequently in this study. This may have been due to
the fact that a urinary catheter was always introduced prior to the operation and a
sample of urine was taken for culture directly after removal. Whenever
pathogenic micro-organisms were found in the culture, antibiotics were given on
the basis of the antibiogram and the urinary infection was documented as a
complication.
It should be taken into account that resection of RRTM was well-tolerated by all
of these patients, despite prior chemotherapy. The relatively young age and the
vigorous premorbid condition enabled the patients to endure the major surgical
procedure relatively well and with only a short postoperative period of
hospitalisation. Depending on the volume as well as on the location of the
residual tumor, adjacent structures or organs may have to be resected. In this
study, nephrectomy had to be performed in four patients, while partial resection
of the aorta followed by reconstruction had to be performed in one patient.
Hendry et al described a series of 231 postchemotherapy RPLNDs. The ipsilateral
kidney was removed with the lymph node mass in 12.5%; the aorta or iliac artery
was resected or grafted in 4% and the vena cava was resected or tied off in 3%.29
Operative mortality rates of between 0% and 1.3% have been reported in the
literature (Table 2). In our study none of the postoperative complications resulted
in mortality. However, one patient died during the
induction of anesthesia. Obduction did not reveal any explanation for the sudden
death of this patient.
The prognosis after the resection of residual disease is generally favourable, with
a 5-year recurrence-free survival of over 85% after resection of necrosis or
mature teratoma and of between 50% and 80% after the resection of viable cancer
followed by additional chemotherapy.8,30 Increased awareness of potential compli-
cations may help to prevent morbidity in patients with disseminated NSTGCT.
However, surgical resection of RRTM remains the only procedure that gives
optimal and accurate information about the histology of the retroperitoneal
residual mass. The long-term remission rate obtained with surgery in adjunct to
chemotherapy still justifies complete resection whenever it is indicated and pos-
sible.
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ABSTRACT
In patients with disseminated nonseminomatous testicular germ cell tumors
(NSTGCT) a retroperitoneal residual tumor mass (RRTM) and/or a pulmonary
residual tumor mass (PRTM) are often present after successful treatment with
cisplatin-based polychemotherapy. Results and complications of postchemotherapy
resection of PRTM were studied and survival was calculated.
In the period 1979 to 1996, 31 patients with a median age of 28 (range 17-44)
years underwent 32 thoracotomies for the resection of an PRTM. A solitary lesion
was encountered nine times (28.1%) and multiple lesions were encountered 23
times (71.9%). The median size was 15 (range 2-60) mm. There were only three
major postoperative complications (9.6%): prolonged ventilation, pneumothorax
and pneumonia. In 16 patients (51.6%), the resected PRTM showed mature
teratoma, while in four patients (12.9%) it showed viable cancer. In 11 patients
only necrosis and/or fibrosis was found (35.5%). Resection of an RRTM had been
performed prior to thoracotomy in 20 patients. There was dissimilarity between
the histology of the resected RRTM and PRTM in 10 out of the 20 patients (50%).
During a median follow-up of 80 (range 2.5-203) months, five patients died from
metastatic disease (16.1%). The 5-year survival rate was 86.8% and the 10-year
survival rate was 82.2%. Owing to the dissimilarity between the histology of the
postchemotherapy resected RRTM and PRTM in 50% of the patients, all sites of
pulmonary residual disease must be resected in patients with disseminated
NSTGCT, irrespective of the histology of previously resected retroperitoneal
residual disease. This approach offers minimal morbidity and a high 10-year
survival rate.
INTRODUCTION
The main selection criteria for pulmonary metastasectomy in patients with
disseminated cancer are: no detectable metastatic site other than the lungs; the
possibility of complete resection of all nodules; and adequate pulmonary reserves
to tolerate resection.1,2 Other variables that may be of prognostic value include
tumor histology, the number of metastatic lesions present and the disease-free
interval between primary treatment and pulmonary recurrence.3 Patients with
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chemoresistant tumors, such as renal cell carcinoma, soft tissue sarcoma,
colorectal carcinoma and melanoma, benefit from early surgical intervention,
because pulmonary metastasectomy is the only curative treatment option.3-5 In
contrast, for patients with disseminated chemotherapy-sensitive tumors, such as
testicular germ cell tumors, the primary treatment consists of chemotherapy. Any
residual disease, including pulmonary metastases, can be removed surgically
afterwards.6
Testicular cancer is the most common solid tumor that affects men aged between
20 and 35 years.7,8 Lymphatic drainage of the testes occurs via the lumbar lymph
nodes, adjacent to the second to the fourth lumbar vertebrae. Haematogenic
spread of testicular cancer may follow two routes: a direct route from the testis to
the lungs, or an indirect route via the lumbar lymph nodes through the thoracic
duct to the subclavian vein and the lungs. Nowadays patients who present with
disseminated nonseminomatous testicular germ cell tumors (NSTGCT) are treated
with cisplatin-based polychemotherapy after initial orchidectomy.9 The
introduction of cisplatin has considerably improved the prognosis of these
patients.10,11 However, after a complete biochemical response to
polychemotherapy, metastatic disease often remains in the retroperitoneum and/or
the lungs. In this particular group of patients, surgical resection of these residual
tumor masses is necessary to distinguish pathologically between necrosis, fibrosis,
mature teratoma or viable cancer.12 Leaving masses with residual viable cancer in
situ involves a serious risk. The presence of viable cancer directs the decision to
administer additional second-line chemotherapy.13 Similarly, masses that contain
mature teratoma may start to grow during follow-up: the so-called growing
teratoma syndrome.14 Resection may then be more complicated than it would have
been shortly after the completion of chemotherapy.
At the University Hospital Groningen, the Netherlands, resection of pulmonary
residual tumor masses (PRTM) is performed after primary chemotherapy in
patients with PRTM who have become serum tumor marker-negative or who have
a mature teratoma component in their primary tumor. The current paper describes
the results and the complications of postchemotherapy resection of an PRTM in
patients with disseminated NSTGCT, treated with orchidectomy and cisplatin-
based polychemotherapy.
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PATIENTS AND METHODS
Between July 1979 and March 1996, 474 consecutive patients with disseminated
NSTGCT were treated at the University Hospital Groningen, the Netherlands.
Clinical staging was performed by physical examination, chest X-ray, serum
tumor markers alpha-fetoprotein (AFP) and human chorionic gonadotrophin
(hCG) and computed tomography (CT) scans of the abdomen and chest.15 In the
early years, bilateral lymphangiography and tomography of the lungs also formed
part of the staging procedure. From 1986 onwards, only CT scanning has been
performed, because it enables more accurate clinical staging than can be achieved
with the former diagnostic procedures.16,17
Out of these 474 patients, 73 had pulmonary metastases (Stage IV according to
the Peckham classification15). All these patients were treated with cisplatin-based
polychemotherapy. A total of four remission-induction courses were administered;
each course had a duration of three weeks. Chemotherapy was administered with
the use of a venous access port (Strato/Infusaid Inc. Norwood, MA, USA18). After
completion of the polychemotherapy, the patients were clinically restaged with
CT scans of the abdomen and chest and monitored for serum tumor markers. If a
patient had become serum tumor marker negative, but still had residual
retroperitoneal and/or pulmonary disease, resection of the residual tumor mass
was performed. Indications for the resection of a retroperitoneal residual tumor
mass (RRTM) have been described previously.19 Indications for the resection of
an PRTM partly depended on the histology of resected RRTM.20 If the resected
RRTM contained necrosis and/or fibrosis only, as a rule, pulmonary
metastasectomy was not performed and the patients were followed-up as
outpatients, unless no further regression occurred. Resection of the PRTM was
performed if the resected RRTM contained mature teratoma or if no surgical
evaluation of the retroperitoneum has been performed. If the resected RRTM
contained viable cancer, second-line chemotherapy was administered. It was
necessary for all the patients who underwent resection of an PRTM to have
adequate pulmonary reserves to tolerate resection.
The standard surgical approach to resect an PRTM was posterolateral
thoracotomy. In individual cases, median sternotomy, anterolateral thoracotomy or
transverse incision was performed. If possible, metastasectomy was performed by
minimal resection or wedge resection. In order to achieve complete resection in
some patients, lobectomy was necessary.
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Perioperative prophylactic antibiotic therapy was given. Anesthetic management
included continuous monitoring of oxygen saturation and intermittent arterial
blood gas analysis. After induction, the FiO2 was maintained at the lowest level
possible to still allow adequate oxygenation (21-25%).21 Generally, epidural
catheters were inserted at the operating theatre prior to thoracotomy for
postoperative pain control. The first attempts at extubation were made within 24
hours of surgery. Intravenous, intramuscular and oral analgesics were used as
required.
Pulmonary complications were divided into two categories based on their severity.
Major complications included the need for mechanical ventilatory support for
more than four days, pneumothorax requiring secondary closed chest tube
drainage and pneumonia documented by positive sputum culture. Minor
complications included the need for mechanical ventilatory support for two to
four days, air leakage for less than one week, minor pneumothorax requiring no
further treatment and atelectasis in the absence of infection. Other complications
were defined as minor if they did not lead to more than two days prolongation of
hospitalisation.
Tumors were classified in accordance with the nomenclature of the World Health
Organisation.22 The histology of the resected PRTM was compared to that of the
primary testicular tumor and to the histology of the resected RRTM if resection
of an RRTM had been performed and if the patient had not been treated with
chemotherapy in the period between resection of the RRTM and PRTM. Survival
was calculated from the date of the first PRTM resection to 1 July 1996, or to the
date of death of the patient. Survival probability was estimated by the Kaplan-
Meier method. The statistical analyses were conducted using the EGRET software
package (Statistics and Epidemiology Corporation, Seattle, WA., USA).
RESULTS
In the group of 73 patients with Stage IV disease, 31 patients (42.5%) underwent
postchemotherapy PRTM resection. The operation was not indicated in the other
42 patients (57.5%) because they had a radiologically complete pulmonary
response, or their serum tumor markers had failed to normalise, or RRTM
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resection had revealed viable cancer. A total of 32 thoracotomies were performed.
One patient underwent two operations. The second thoracotomy was an elective
operation for the management of metastases in the contralateral lung, after the
other lung had been operated on four weeks earlier.
The median age of the 31 patients was 28 (range 17-44) years. The median
interval between the last dose of combination chemotherapy and PRTM resection
was 109 days (range 31 days to 9 years). In two of these patients the interval was
very long, namely six and nine years, respectively. In both patients only an
PRTM was detected, without any retroperitoneal disease. In 20 patients (64.5%)
RRTM resection was performed between polychemotherapy and PRTM resection.
The median interval between RRTM resection and PRTM resection was 81 days
(range 0 days to 8.9 years). In two patients, PRTM resection was performed in
the same session as the RRTM resection. The surgical approach in these two
patients was laparotomy with median sternotomy (3.1%) and laparotomy and left
posterolateral thoracotomy (3.1%), respectively. In the other 30 thoracotomies, the
surgical approach was 13 left posterolateral thoracotomies (40.6%), nine right
posterolateral thoracotomies (28.2%), six median sternotomies (18.8%), one
anterolateral thoracotomy on the left and right (3.1%), and one transverse incision
with transverse sternotomy (3.1%). Minimal resection was performed in six
thoracotomies (18.8%), wedge resection in 24 thoracotomies (75.0%), lobectomy
in one thoracotomy (3.1%) and wedge resection together with lobectomy in the
remaining thoracotomy (3.1%). In nine cases a solitary lesion was removed
(28.1%) and in 23 cases multiple lesions (71.9%) were removed. The median
number of metastases removed was two (range 1-15) and the median size was 15
(range 2-60) mm.
Perioperative complications. There were five complications in four patients
(12.9%). In two patients a small air leak was accepted at the time of chest
closure. In one of these patients and in one other patient, an accidental arterial
lesion caused major bleeding. In the remaining patient, separate ventilation of
both lungs was not possible because of retention of secretion. In this patient,
suction by bronchoscopy was performed.
Major postoperative complications. Three major complications occurred (9.6%).
Prolonged mechanical ventilation for five days was necessary in one patient who
underwent resection of bilateral PRTM by median sternotomy. A second patient
needed closed chest tube drainage for a pneumothorax one day after right
posterolateral thoracotomy. The third patient developed pneumonia three days
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after left posterolateral thoracotomy. This patient was treated successfully with
antibiotics. There was no procedure-related mortality.
Table 1. Complications associated with 32 thoracotomies for
pulmonary metastasectomy in 31 patients
Perioperative
Air leakage 2
Accidental arterial lesion 2
Hypoventilation 1
Total peroperative complications 5





Total major postoperative complications 3






Allergic reaction to antibiotics 1
Frozen shoulder 1
Neurological complications 3
Total minor postoperative complications 11
in number of patients 11 (35.5%)
Minor postoperative complications. There were 11 minor postoperative
complications (35.5%). One patient required prolongation of postoperative
ventilation for one day, because of insufficient oxygenation. Two patients
experienced air leakage for two and three days, respectively. In two patients a
small postoperative pneumothorax occurred for which no further treatment was
103
Resection of PRTM in NSTGCT
necessary. Atelectasis without infection was diagnosed in one patient and another
patient developed an allergic reaction to the prophylactic antibiotics; neither of
them needed any further treatment. One patient had a frozen shoulder on the right
side after right posterolateral thoracotomy. This was treated successfully with
physiotherapy. Postoperative neurological complications consisted of transient
paresthesia in two patients and of unilateral miosis in one patient.
In this group of 31 patients, the median postoperative period of hospitalisation
was eight (range 4-14) days. Perioperative and postoperative complications are
shown in Table 1.
In all 31 patients, complete resection of the PRTM was achieved; 20 of them had
undergone also a laparotomy. However, although CT scanning of the abdomen
had revealed a small RRTM, in three patients no abnormalities were found at
laparotomy and therefore resection was not performed. So, a total of 17 patients
eventually underwent a resection of RRTM. There was a complete radiological
response in the retroperitoneum in eleven patients. Therefore, laparotomy was not
performed and they underwent thoracotomy alone.
The histologies of the primary tumor, the resected RRTM and the resected PRTM
are shown in Table 2. Mature teratoma was found in the PRTM in 16 patients
(51.6%). Four out of the 20 patients (20.0%) who had undergone both RRTM and
PRTM resection, had mature teratoma in the RRTM, but not in the PRTM, while
three patients (15.0%) had mature teratoma in the PRTM, but not in de RRTM. In
four patients (12.9%) histological examination of the resected PRTM revealed
viable cancer, despite normalisation of the serum tumor markers. In three of them,
the malignant components were choriocarcinoma, embryonal carcinoma and yolk
sac tumor, respectively; no viable cancer was found in the RRTM of any of them.
In the remaining patient, the resected PRTM revealed a second primary
malignancy, consisting of chondrosarcoma and rhabdomyo-sarcoma. These
components were also found in the resected RRTM. In this particular patient the
indication to perform thoracotomy was therefore slightly different; surgery was
also aimed to be curative.
Five patients had necrosis and/or fibrosis only in the resected RRTM. In three out
of these five patients also necrosis was found in the PRTM. In the other two
patients mature teratoma and embryonal carcinoma, respectively, was found in the
PRTM. In the latter two patients the decision to resect the PRTM was made at
the same time as the decision to resect the RRTM. In one patient both resections
were performed in the same session, in the other patient the interval between
resection of RRTM and PRTM was 21 days.
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Table 2. Histological findings in the primary tumor,
abdomen and chest
Patient Orchidectomy rRRTM rPRTM
1 E+M M M
2 E+C+M - N+F
3 E+M - M
4 E+M N+F+M N+F
5 E+M+Y 0 M
6 E+M+I+S M+ sec.mal sec.mal
7* E+C+M+Y - N
8 C - N
9 E+M+I - F+M
10 C 0 N+F+C
11 E+M+I+S - M
12 E+M+Y F N
13* E+Y N+F N
14 E+C+M N N
15 E+M+I F+M M
16* E - 1.F+M / 2.N
17 E+M+I+Y - F+M
18 E N+M F+M
19* E+C+M+I+Y M M
20 E F+M M
21 C+M N+F+M N
22 C+M M N
23 E+S - N
24 E+M+S 0 M
25 E+M+S - M
26 E+C+M+I+Y - F+M
27 E+M+Y F M
28* E N+F N+E
29 E+C+M N+F+M M
30 E+C+I+Y F+M N+F
31 E+M+I+Y M M+Y
rRRTM, resection of retroperitoneal residual tumor mass; rPRTM, resection of pulmonary
residual tumor mass; C, choriocarcinoma; E, embryonal carcinoma;
F, fibrosis; I, immature teratoma; M, mature teratoma; N, necrosis; S, seminoma;
Y, yolk sac tumor; sec. mal., second primary malignancy; 0, no palpable abnormalities; *,
deceased; -, resection not performed because of complete radiological response.
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There was dissimilarity between the histological findings at the two sites in 10
out of the 20 patients (50.0%) who had undergone both RRTM and PRTM
resection.
The median follow-up duration was 80 months (6.7 years), range 2.5 to 203
months. During the course of follow-up, five patients died (16.1%) from
metastatic disease after 2.5, 9, 25, 26 and 65 months, respectively. One of these
patients suffered massive gastro-intestinal bleeding of unknown origin during
second-line polychemotherapy treatment. At the time of this study the remaining
26 patients (83.9%) were alive with no evidence of disease.
Figure 1 shows the Kaplan-Meier survival curve of the 31 patients after their first
pulmonary metastasectomy. Five-year survival rate was 86.8% (95% CI: 68.5-
94.8%) and the 10-year survival rate was 82.2% (95% CI: 62.0-92.3%).
Figure 1. Survival curve (Kaplan-Meier) of 31 patients after




The indication for PRTM resection in patients with NSTGCT is different from
that of patients with pulmonary metastases from other malignancies. In general,
surgery is the only curative option for patients with chemoresistant tumors. For
example, after curative resection of pulmonary metastases in patients with
pulmonary metastases from soft tissue sarcomas, a 5-year survival rate of 25%
can be achieved.23 Testicular cancer reacts very well to cisplatin-based
polychemotherapy. In patients with NSTGCT, postchemotherapy resection of
residual radiographically detectable abnormalities is important, because it enables
a histological diagnosis. Resection of metastases with mature teratoma is
necessary to exclude the risk of the growing teratoma syndrome;14 similarly, it is
not desirable to leave masses with residual viable cancer in situ. Therefore,
resection of RRTM and PRTM are well-established and effective adjunctive
procedures in patients with NSTGCT.
It is generally recommended that after chemotherapy, all patients with resected
viable cancer should undergo second-line polychemotherapy, with the aim of
improving recurrence-free survival.12,24-27 Nevertheless, despite this salvage
polychemotherapy treatment, the recurrence-free survival of these patients is
substantially poorer than that of patients whose metastases contain necrotic debris
or fibrosis.9,12 Moreover, Steyerberg et al. found that the incomplete resection of
residual tumor was associated with a significantly poorer prognosis than complete
resection.28 The current study describes 31 patients who underwent complete
resection of an PRTM. At present, twenty-six of them are alive without any
evidence of disease, despite the fact that viable cancer was found in the
metastases of three of them (11.5%). In two patients, late pulmonary metastases
were detected after six and nine years, respectively. Both patients are still alive,
without any evidence of disease. Baniel et al. reported on 47 patients with
testicular germ cell cancer who recurred more than five years after the successful
management of their initial disease.29 They stated that surgery is the preferred
mode of therapy for late recurrence, because chemotherapy is only moderately
successful in these cases.
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Overall 10-year survival rates of 23% and 30% have been reported among
patients with pulmonary metastases from cancer at various primary sites.2,4,23 The
high recurrence-free 10-year survival rate of our patients (82.2%) indicates that
in patients with NSTGCT, complete resection of an PRTM can form an extremely
effective curative approach. Our findings also confirm those reported by other
authors, although the long-term recurrence-free survival rates vary from 50% to
87% after surgery in adjunct to chemotherapy.28,30,31 Besides the advantages of the
procedure, thoracotomy also has disadvantages. The perioperative complication
rate of 12.9%, the postoperative major complication rate of 9.6%, and the
postoperative minor complication rate of 35.5% are comparable with those
mentioned in the literature, in which the complication rates range from 6.3% to
39%.2,6,32-35 These complications include pneumonia 3.8% to 22%; prolonged
thoracic drainage for more than one week 3.2% to 17.3%; wound infection 3% to
11.3%; postoperative hemorrhage leading to reoperation 1% to 3%; secondary
closed chest tube drainage up to 5%; and prolonged mechanical ventilation 3.2%
to 7.5%. In our study, no procedure-
related mortality occurred. However, in the literature, mortality rates of up to
5.3% have been reported.6,36,37
At the University Hospital Groningen, the Netherlands, the decision to resect an
PRTM in patients with both residual retroperitoneal and pulmonary disease, is
partly made on the basis of the histological diagnosis of the resected RRTM, e.g.
necrosis/fibrosis or mature teratoma. The results of this study indicate that this
may not be a sound policy, because in 10 out of the 20 patients (50.0%) the
histological findings in the resected RRTM were different from those in the
PRTM. In four of these patients (20.0%) mature teratoma was found in the
resected RRTM, but not in the resected PRTM; in three patients (15.0%) mature
teratoma was found in the resected PRTM, but not in the resected RRTM; in
three patients (15.0%) viable cancer was found in the resected PRTM but not in
the resected RRTM.
Other authors have also indicated that the histology at one resected site does not
necessarily predict the histology at other sites in patients with multiple distant
metastases. Recently, Brenner et al. have described 24 patients who underwent
simultaneous resection of residual postchemotherapy masses in the
retroperitoneum and chest.35 They reported that in six patients (25%) the
pathology in the chest differed from that in the abdomen. Tiffany et al. described
23 patients with stage III NSTGCT who underwent both retroperitoneal lymph
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node dissection (RPLND) and thoracotomy.38 The histological findings at the two
sites were dissimilar in 35%. In the separate series described by Donohue et al.,13
Qvist et al.39 and Mandelbaum et al.40 there was dissimilarity between the
thoracotomy and laparotomy histologies in 29%, 47% and 29%, respectively.
Table 3 shows an overview of recent experience with dissimilarities in the
histologies of resected RRTM and RPTM.
Table 3. Dissimilarities in the histologies of the resected
residual retroperitoneal and pulmonary tumor masses
Number of Number of
patients Dissimilarities
Mandelbaum et al. ’8340 24 7 (29%)
Donohue et al. ’8413 24 7 (29%)
Tiffany et al. ’8638 23 8 (35%)
Qvist et al. ’9139 15 7 (47%)
Brenner et al. ’9635 24 6 (25%)
Gels et al. ’97 20 10 (50%)
Toner et al. described 39 patients who underwent 47 separate procedures for
pulmonary parenchymal nodules. Three out of the 8 patients who underwent
bilateral thoracotomy (37.5%) showed different histologies in the masses resected
from each lung.30 Recently, Steyerberg et al. have demonstrated that necrosis was
found at thoracotomy in 89% of those patients with necrosis at RPLND.41 In the
present study only three out of the five patients (60%) with necrosis and/or
fibrosis in the resected RRTM had also necrosis in the PRTM. The resected
PRTM of the other two patients showed mature teratoma and embryonal
carcinoma, respectively. If there was only necrotic and/or fibrotic tissue in the
retroperitoneum, the percentage of necrotic tissue in the chest differs from 50% to
100% in the literature.13,35,38-43 Because the histology of the PRTM can not be
predicted in all patients based on the histology of the resected RRTM, it is
justified to perform a pulmonary resection, even in patients with necrosis in the
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retroperitoneum.
The current retrospective study demonstrates that an aggressive surgical approach
to residual pulmonary disease in disseminated NSTGCT after cisplatin-based
polychemotherapy is highly justified. All the sites of residual disease must be
resected, irrespective of the histological results of the initial RRTM resection. An
aggressive approach to testicular cancer using combined treatment modalities
offers the best recurrence-free and overall survival, with minimal treatment-related
morbidity and no mortality.
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Over the past twenty years, the role of surgery has been influenced considerably
by many new developments in the diagnosis and treatment of patients with
malignant testicular germ cell tumors. This thesis describes a number of aspects
of the present role of surgery in the treatment of patients with malignant testicular
germ cell tumors in the light of five studies. The majority of patients were treated
for a nonseminomatous testicular germ cell tumor (NSTGCT).
In the general part of the Introduction, brief descriptions are given of the
epidemiology and etiology of malignant testicular tumors. Dissemination,
symptomatology and diagnosis are discussed. Overviews are presented of the
staging classification according to Peckham and the histological classification of
the World Health Organisation; a description is also given of primary tumor
staging according to the guidelines of the Union Internationale Contre le Cancer.
The second part of the Introduction deals extensively with historical and recent
developments in the diagnosis and treatment of patients with malignant testicular
germ cell tumors. Particular attention is paid to the changing role of surgery.
Over the years, the value of surgery has shifted from being primarily therapeutic
to being more diagnostic in an adjuvant setting; developments such as the
discovery and application of very effective cisplatin-based polychemotherapy and
serum tumor markers, and improvements in clinical staging through computed
tomography (CT scanning) are responsible. In addition, surgery plays a facilitating
role in monitoring the effect of treatment with polychemotherapy.
The research questions which formed the basis of this thesis are formulated at the
end of the Introduction and addressed in the five chapters that follow.
Chapter II describes 154 patients with clinical stage I NSTGCT who were treated
according to the wait-and-see policy between 1982 and 1992. These patients were
followed-up prospectively over a ten-year period by means of solely awaiting the
progress of events. This means that if there were no demonstrable metastases after
orchidectomy, further management over the subsequent years was confined to
frequent outpatient check-ups. At each follow-up visit, a patient underwent
physical examination and the serum tumor markers human chorionic
gonadotrophin (hCG) and alpha-fetoprotein (AFP) were determined. In addition,
chest X-rays and CT scanning of the abdomen and chest were conducted
according to a fixed schedule.
Records were kept of the number of patients who developed metastases, the
interval between orchidectomy and the diagnosis of metastases and how the
metastases were detected. Using multivariate logistic regression analyses, a
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search was made for unfavourable prognostic factors for the development of
metastases. During a median follow-up of seven (range 2-12) years, 42 patients
developed metastases (27.3%). All the cases of disseminated disease were
detected within two years of orchidectomy, while more than 90% of them were
even detected within the first year. The vast majority were detected by increased
levels of serum hCG and/or AFP and by CT scanning. None of them were
detected via the chest X-ray. Development of metastases appeared to be related to
the presence of vascular invasion of the primary tumor, an embryonal carcinoma
component in the primary tumor, an increased hCG level prior to orchidectomy
and the absence of mature teratoma in the primary tumor. Vascular invasion
proved to be the only independent risk factor for the development of metastases
(P=.001). After treatment with cisplatin-based polychemotherapy, the survival rate
in the total group of 154 patients was 98.7%. Two patients died of progressive
disease, but it should be mentioned that one of them refused to be treated with
polychemotherapy and opted instead for homeopathic treatment.
It can be concluded that it is justified to apply a wait-and-see policy to patients
with clinical stage I NSTGCT. This also applies to the possible development of
metastases in patients with unfavourable prognostic factors. Owing to the fact that
all metastatic disease developed within two years of orchidectomy, it does not
appear to be necessary to continue follow-up for 10 years. In the light of reports
in the literature on patients who developed metastases after two years, it is
considered advisable to continue follow-up for five years. Furthermore, it does not
seem to be worthwhile to take chest X-rays, because none of the metastatic
disease was detected in this manner. These findings have led to the formulation of
a new wait-and-see follow-up schedule for patients with clinical stage I NSTGCT.
Chapter III evaluates the additional value of a new serum tumor marker,
TRA-1-60, for the follow-up of patients in the wait-and-see group. TRA is the
abbreviation for Terato Related Antigen.
In 1991, Marrink developed a serum immunoenzymometric assay for the
detection of TRA-1-60 reactive antigen. This antigen is released into the serum of
patients who have an embryonal carcinoma component in the primary tumor. As
embryonal carcinoma, with a frequency of 70%, is by far the most common
histological component of NSTGCT, TRA-1-60 formed a promising potential
tumor marker. The upper normal reference value and the serum half-life of
TRA-1-60 were determined and a possible relationship was investigated between
an increased serum TRA-1-60 level at the time of orchidectomy and the
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development of metastases. To establish the normal serum level, TRA-1-60 was
measured in 100 healthy men in the same age group as the patients with an
NSTGCT. The upper normal reference value was found to be 230 U/ml. The
serum half-life time of TRA-1-60 was determined from the sera of five patients
without metastases who had an initial value of >850 U/ml in combination with
strongly increased hCG and/or AFP levels prior to orchidectomy. After
orchidectomy, their serum tumor marker levels were determined two or three
times per week until the hCG and/or AFP levels had normalised. As the tumor
markers hCG and AFP in these patients normalised according to their known half-
lives: two days for hCG and six days for AFP, it could be assumed that TRA-1-
60 would also normalise according to its own half-life. The half-life of TRA-1-60
was found to be 9.5 days. Sensitivity, specificity and positive and negative
predictive values of the three tumor markers, hCG, AFP and TRA-1-60, were
calculated and proved to be comparable. In the 42 patients with clinical stage I
NSTGCT who developed metastases during follow-up, the TRA-1-60 levels were
evaluated one month prior to the detection of metastases by CT scanning and at
the time that metastases were confirmed by CT scanning. One month prior to
detection, 21 out of the 42 patients (50.0%) were found to have elevated TRA-1-
60 levels. In 10 of them, it was the only tumor marker that was elevated. At the
time that metastases were confirmed by CT scanning, 24 patients had increased
TRA-1-60 levels, while in nine of them it was the only elevated tumor marker.
Disease free survival was significantly poorer in patients with a TRA-1-60 level
of >500 U/ml at the time of orchidectomy (P=.015).
It can be concluded that TRA-1-60 has definite additional value to hCG and AFP.
Monitoring a combination of these three tumor markers can be expected to
improve the early detection of metastases.
Chapter IV describes 132 patients with disseminated testicular cancer who were
treated with polychemotherapy via a Venous Access Port (VAP) between 1983
and 1994. Perioperative and late complications related to VAP implantation were
recorded and multivariate analyses were performed to detect any factors that
could predict the occurrence of complications. In the literature, various
complications of VAP implantation have been described, but contrary to our
investigation, none of the studies were performed on a homogeneous group of
patients.
The median age of the patients was 28 (range 16-55) years. Perioperative
complications occurred in five patients (3.7%); two patients had a pneumothorax,
two had severe blood loss and one had a mediastinal bleeding. The VAPs
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remained in situ for a median of 413 (range 7-1607) days. In 31 patients
(23.0%), 42 late complications were recorded (31.0%). The total number of late
complications corresponded with 0.76 complication episodes per 1000 patient
days. These late complications comprised: system obstruction in 13 patients
(9.6%), thrombosis in 11 patients (8.1%), infection in six patients (4.4%), catheter
defect in six patients (4.4%), extravasation in four patients (3.0%) and local skin
necrosis in two patients (1.5%). Significantly more complications occurred in
patients who had received intravenous chemotherapy prior to VAP implantation
(P<.001). This difference was demonstrated with both multivariate and univariate
analysis. In addition, univariate analysis showed that more complications occurred
with VAP implantation under local anesthesia than under general anesthesia. In
order to make a valid comparison of the results of this study with those in the
literature, the complication incidence of various other authors was calculated and
expressed as the number of episodes per 1000 patient days. In this way it was
found that broadly speaking, our results agreed with those reported in the
literature, but it appeared that the VAPs implanted into the University Hospital
Groningen patients remained in situ for a relatively longer period than those at
other clinics. This was because it was standard policy at the University Hospital
Groningen to leave the VAP in situ for up to one year after the completion of
chemotherapy, so that if further chemotherapy was required to treat additional
residual disease it could be administered via the same VAP. However, as the risk
of late catheter defects appeared to increase, it is worthwhile to consider removal
at an earlier stage.
It can be concluded that the implantation and use of a VAP forms a safe means
of administering polychemotherapy. The only independent risk factor for the
development of late complications was a history of polychemotherapy
administration prior to VAP implantation.
Chapter V presents a study on 112 patients who underwent resection of
retroperitoneal residual tumor mass (RRTM) after the completion of cisplatin-
based polychemotherapy. Attention is focused on establishing the histology of the
residual tumor, in order to be able to evaluate the ultimate effect of treatment.
RRTM was found to comprise necrosis and/or fibrosis, mature teratoma or viable
cancer. The resection of necrosis or fibrosis is not actually necessary and does not
have any therapeutic consequences, whereas the resection of mature teratoma is
worthwhile to prevent the growth of potentially malignant cells. If a residual
tumor mass contains viable cancer, chemotherapy should be continued.
The histology of the RRTM and surgical morbidity were examined. In addition, a
search was made for factors that might explain why complications arose. The
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median size of the resected RRTM was 4 cm, ranging from 0-18 cm. In ten
patients (9.0%) the RRTM contained viable cancer; in 49 patients (44.1%) only
necrosis and/or fibrosis were found; in 49 other patients (44.1%) the RRTM
contained mature teratoma and in three patients (2.8%) no residual tumor mass
was found at laparotomy. A total of 26 complications occurred in 20 patients
(18.0%). The most frequent complication was urinary tract infection, which
occurred in nine patients (8.1%). One patient died during the induction of
anesthesia. Postmortem examination did not reveal any clear indications about the
cause of death. There were no significant relationships between the occurrence of
complications and the age of the patient, the size of the residual tumor, the
operative duration, previous laparotomy or the histological findings. In the light
of recent literature data, the discussion centres on the complications that occurred
in these patients and compares them to those reported by authors from other
clinics; attention is also paid to techniques for predicting the histology of residual
tumor.
It can be concluded that surgical resection of RRTM should be considered as the
golden standard for evaluating the effect of polychemotherapy treatment. The
surgical technique is relatively safe, with a morbidity of 18.0%, which mainly
comprises urinary tract infection (8.1%). Knowledge of the potential
complications associated with this intervention will help to limit their occurrence.
Chapter VI reveals that after radical treatment with polychemotherapy, residual
lesions may not only be found in the retroperitoneum, but also in the lungs. The
indication for thoracotomy in patients with NSTGCT is completely different from
that in other disseminated malignancies. In general, surgery for the latter group of
patients is the only remaining curative option, whereas in patients with NSTGCT
the indication for thoracotomy chiefly entails evaluation of the effect of
chemotherapy, or prevention of the growing teratoma syndrome. At the University
Hospital Groningen, the decision to perform thoracotomy partly depended on the
histology of the retroperitoneal residual tumor mass. It was expected that a
pulmonary residual tumor mass (PRTM) would have the same histology as the
RRTM. If the RRTM contained only necrosis or fibrosis, thoracotomy was not
generally considered to be necessary; if it contained mature teratoma, thoracotomy
was performed to prevent the growing teratoma syndrome; and if it contained
viable cancer, the patient firstly received further polychemotherapy.
The results and complications of resection of residual tumor mass from the lungs
were evaluated in 31 patients with a stage IV NSTGCT; survival was calculated.
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In the patients who had previously undergone laparotomy, the histology of the
PRTM was compared to that of the RRTM. Between 1979 to 1996, 32
thoracotomies were performed on 31 patients. In nine cases (28.2%) a solitary
metastasis was removed and in 23 cases (71.8%) multiple metastases were
removed. The median size was 15 mm, ranging from 2-60 mm. There were five
perioperative complications in four patients (12.5%): minimal air leakage in two
cases, accidental arterial bleeding in two cases and mucous retention in one case
that interfered with artificial ventilation. Three serious postoperative complications
occurred (9.4%): one patient needed artificial ventilation for five days, one patient
had a pneumothorax which required drainage and the third patient developed
pneumonia a few days after surgery. There were also 11 less serious postoperative
complications (34.4%), which did not lead to prolongation of the period of
hospitalisation by more than two days.
Histological examination of the resected PRTM revealed mature teratoma in 16
patients (51.6%), necrosis and/or fibrosis in 11 patients (35.5%) and viable cancer
in four patients (12.9%). In 20 out of the 31 patients, laparotomy had been
performed prior to thoracotomy to resect RRTM. In 10 out of these 20 patients
(50.0%) the histology of the retroperitoneal tumor mass did not match that of the
pulmonary tumor mass. During a median follow-up of seven (range 0.2-16.9)
years, five patients died from the disease. The five-year survival rate was 86.6%,
while the 10-year survival rate was 82.2%.
It can be concluded that all residual tumor masses should be surgically resected
from patients who have received chemotherapy for a NSTGCT, irrespective of the
histology of the lesion(s) removed first. This policy, with minimal morbidity, can




Onder invloed van vele nieuwe ontwikkelingen in de diagnostiek en behandeling
van patiënten met maligne kiemceltumoren van de testis, is de rol van de
chirurgie de laatste twintig jaar aanzienlijk gewijzigd. In dit proefschrift wordt
aan de hand van vijf artikelen een aantal aspecten van de huidige rol van de
chirurgie bij de behandeling van patiënten met maligne kiemceltumoren
beschreven. Het merendeel van de beschreven patiënten werd behandeld wegens
een non-seminoma testis tumor (NSTT).
In de inleiding wordt in het algemene deel kort ingegaan op de epidemiologie en
de etiologie van maligne testistumoren. Metastaseringspatroon, symptomatologie
en diagnostiek worden behandeld. De in gebruik zijnde stadiumindeling volgens
Peckham en de histologische classificatie volgens de nomenclatuur van de World
Health Organisation worden weergegeven. Ook het vaststellen van het stadium
van de primaire tumor volgens de richtlijnen van de Union Internationale Contre
le Cancer wordt beschreven.
In het tweede deel van de inleiding wordt uitgebreid ingegaan op de historische
en recente ontwikkelingen in de diagnostiek en behandeling van patiënten met
maligne kiemceltumoren van de testis. Hierbij komt vooral de veranderende rol
van de chirurgie aan de orde. Mede door het beschikbaar komen van zeer
effectieve, op cisplatine gebaseerde polychemotherapie en de mogelijkheid om
tumormerkstoffen in het serum van de patiënt aan te tonen, en daarnaast een
verbeterde klinische stagering door de computertomografie (CT-scan), is de
waarde van de chirurgie verschoven van een voornamelijk therapeutische naar een
meer diagnostische, onder andere door de adjuvante setting. Bovendien heeft de
chirurgie een faciliterende rol voor de beoordeling van de effectiviteit van de
behandeling met polychemotherapie. Aan het einde van de inleiding worden de
vraagstellingen geformuleerd die de basis vormden voor dit proefschrift. In de
daarop volgende vijf hoofdstukken komt de beantwoording van deze vragen aan
de orde.
In Hoofdstuk II worden 154 patiënten met klinisch stadium I NSTT besproken die
in de periode van 1982 tot 1992 zijn behandeld volgens de ’wait-and-see policy’.
Deze patiënten zijn gedurende tien jaar prospectief vervolgd met een afwachtend
beleid. Dit beleid houdt in dat, wanneer er na de orchidectomie geen
metastasering is aangetoond, volstaan wordt met zeer frequente controle in de
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eerstvolgende jaren. Tijdens de poliklinische controles wordt steeds een
lichamelijk onderzoek uitgevoerd en zijn de serum tumormerkstoffen humaan
choriogonadotropine (hCG) en alpha-foetoproteïne (AFP) bepaald. Daarnaast zijn,
volgens een vaststaand schema, röntgenfoto’s van de thorax en CT-scans van het
abdomen en de thorax gemaakt. Het aantal opgetreden recidieven, het tijdsinterval
tussen orchidectomie en recidief en de manier waarop het recidief is ontdekt zijn
bestudeerd. Verder is onderzocht of er prognostisch ongunstige factoren zijn voor
het ontstaan van een recidief. Hiertoe zijn multivariate logistische regressie
analyses uitgevoerd. Gedurende een mediane follow-up van zeven jaar (spreiding
2-12 jaar) werd bij 42 patiënten een recidief gevonden (27,3%). Al deze
recidieven zijn binnen twee jaar na de orchidectomie gedetecteerd, meer dan 90%
zelfs in het eerste jaar. Veruit de meeste (97,6%) zijn opgespoord door een
verhoging van het serum hCG en/of AFP en door afwijkingen op de CT-scans.
Bij geen enkele patiënt werd het recidief ontdekt op de röntgenfoto van de thorax.
Het optreden van een recidief bleek gerelateerd te zijn aan de aanwezigheid van
vasculaire invasie door de primaire tumor, aan een embryonaalcel carcinoom
component in de primaire tumor, aan een verhoogd hCG voor de orchidectomie
en aan de afwezigheid van matuur teratoom in de primaire tumor. Alleen de
aanwezigheid van vasculaire invasie bleek een onafhankelijke risicofactor voor het
ontstaan van een recidief te zijn (P=.001). Na behandeling met op cisplatine
gebaseerde polychemotherapie van de patiënten die een recidief kregen, was de
overleving voor de hele groep van 154 patiënten 98,7%; twee patiënten zijn
overleden door progressie van de ziekte. Hierbij moet worden opgemerkt dat één
van deze twee patiënten heeft geweigerd zich te laten behandelen met
polychemotherapie, en er de voorkeur aan gaf homeopathisch behandeld te
worden. Geconcludeerd wordt dat de ’wait-and-see policy’ voor patiënten met
klinisch stadium I NSTT een verantwoord beleid is. Zelfs bij patiënten met
prognostisch ongunstige factoren kan het ontstaan van eventuele metastasering
worden afgewacht. Het lijkt echter niet nodig patiënten tien jaar lang te vervolgen
wanneer alle recidieven binnen twee jaar worden opgespoord. Omdat in de
literatuur wel patiënten zijn beschreven die na twee jaar nog een recidief kregen,
is er toch voor gekozen om de duur van de follow-up op vijf jaar te brengen.
Verder lijkt het niet zinvol röntgenfoto’s van de thorax te maken, omdat een
recidief bij deze patiënten hierdoor nooit werd opgespoord. Met deze twee
belangrijke veranderingen is er een nieuw ’wait-and-see’ follow-up schema
geformuleerd voor patiënten met klinisch stadium I NSTT.
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In Hoofdstuk III wordt de additionele waarde van de nieuwe serum
tumormerkstof TRA-1-60 in de follow-up van patiënten uit de ’wait-and-see’
groep bepaald. De afkorting TRA staat voor Terato Related Antigen. In 1991
ontwikkelde Marrink een serum immunoenzymometrische test voor de detectie
van TRA-1-60 reactief antigeen. Dit antigeen komt vrij in het serum van patiënten
die een embryonaalcel carcinoom component in de primaire tumor hebben. Omdat
embryonaalcel carcinoom met 70% de meest voorkomende histologische
component van NSTT is, zou TRA-1-60 een veelbelovende potentiële
tumormerkstof kunnen zijn. Normaalwaarde en halfwaardetijd zijn berekend, en
een mogelijke relatie tussen een verhoogde TRA-1-60 ten tijde van de
orchidectomie en het ontstaan van een recidief is onderzocht. Om de
normaalwaarde te kunnen bepalen is bij 100 gezonde mannen in dezelfde
leeftijdsgroep als de patiënten met NSTT, het serum TRA-1-60 bepaald. De
normaalwaarde is vastgesteld op 230 U/ml. De halfwaardetijd is berekend door
TRA-1-60 te bepalen uit de sera van vijf patiënten zonder recidief met een initiële
waarde van >850 U/ml én een sterk verhoogde waarde van hCG en/of AFP ten
tijde van de orchidectomie. Bij deze patiënten werden na de orchidectomie twee
tot drie maal per week de tumormerkstoffen in het serum bepaald totdat
normalisatie van hCG en/of AFP ontstond. Omdat de tumormerkstoffen bij deze
patiënten volgens de bekende halfwaardetijden van twee dagen voor hCG en van
zes dagen voor AFP normaliseerden, mocht worden aangenomen dat ook de TRA-
1-60 volgens haar eigen halfwaardetijd zou normaliseren. De halfwaardetijd voor
TRA-1-60 blijkt 9,5 dagen te zijn. Sensitiviteit, specificiteit en positieve en
negatieve voorspellende waarden van de drie tumormerkstoffen hCG, AFP en
TRA-1-60 zijn berekend en bleken in dit onderzoek vergelijkbaar te zijn. Bij de
42 patiënten met een klinisch stadium I, die in de follow-up een recidief
ontwikkelden, is het TRA-1-60 bepaald een maand voor het CT-bevestigde
recidief, en ten tijde van het CT-bevestigde recidief. Een maand voor het recidief
bleken 21 van de 42 patiënten (50,0%) al verhoogde waarden van TRA-1-60 te
hebben. TRA-1-60 was hierbij de enige verhoogde tumormerkstof in tien
patiënten. Ten tijde van het recidief hadden 24 patiënten een verhoogd TRA-1-60,
terwijl in negen hiervan TRA-1-60 de enige verhoogde tumormerkstof was.
Patiënten met een TRA-1-60 van >500 U/ml ten tijde van de orchidectomie
bleken een significant slechtere recidief-vrije overleving te hebben (P=.015). Uit
dit onderzoek is geconcludeerd dat
TRA-1-60 zeker een additionele waarde heeft naast het hCG en AFP. De




In Hoofdstuk IV worden 132 patiënten met gedissemineerde testistumoren
besproken die in de periode van 1983 tot 1994 via een Venous Access Port
(VAP) polychemotherapie kregen toegediend. Perioperatieve en late complicaties
gerelateerd aan de VAP implantatie zijn beschreven en een multivariate analyse is
verricht om eventuele factoren aan te tonen die een complicatie zouden kunnen
voorspellen. In de literatuur zijn wel reeds complicaties van de VAP beschreven,
maar nog niet eerder bij een homogene patiëntengroep, zoals in dit onderzoek. De
mediane leeftijd van de patiënten was 28 jaar (spreiding 16-55 jaar).
Perioperatieve complicaties ontstonden bij vijf patiënten (3,7%) en bestonden bij
twee patiënten uit een pneumothorax, bij twee andere patiënten uit hevig
bloedverlies en uit een mediastinale bloeding bij de laatste patiënt. De VAPs
bleven gedurende een mediane tijd van 413 dagen in situ (spreiding 7 tot 1607
dagen). Bij 31 patiënten (23,0%) ontstonden 42 late complicaties (31,0%). Het
totale aantal late complicaties correspondeerde met 0,76 complicatie episodes per
1000 patiënt dagen. Deze late complicaties bestonden uit: systeemobstructie bij 13
patiënten (9,6%), trombose bij 11 patiënten (8,1%), infectie bij zes patiënten
(4,4%), catheterdefect bij zes patiënten (4,4%), extravasatie bij vier patiënten
(3,0%) en lokale huidnecrose bij twee patiënten (1,5%). Late complicaties traden
significant vaker op bij patiënten die voorafgaand aan de VAP implantatie al
intraveneus chemotherapie toegediend hadden gekregen (P<.001). Dit verschil
werd zowel bij multivariate als univariate analyse aangetoond. Daarnaast werd bij
univariate analyse gevonden dat er meer complicaties optraden bij VAP
implantaties onder lokaal anesthesie, dan bij VAP implantaties onder narcose. Om
de resultaten van dit onderzoek goed te kunnen vergelijken met de resultaten in
de literatuur is van verschillende andere auteurs ook de complicatie incidentie
berekend en uitgedrukt in het aantal episodes per 1000 patiënt dagen. Zo bleek
dat onze resultaten in grote lijnen overeenkwamen met de literatuurgegevens. Wel
bleven de VAPs bij de patiënten van het Academisch Ziekenhuis Groningen
relatief lang in situ, vergeleken met andere klinieken. Dit komt doordat de VAP
bij deze patiënten standaard tot een jaar na afloop van de cytostatische
behandeling in situ blijft, zodat bij een eventueel recidief, de polychemotherapie
opnieuw via de VAP toegediend kan worden. Het risico op late catheterdefecten
lijkt hierdoor echter toe te nemen, zodat een eerdere verwijdering van de VAP te
overwegen is. Uit dit onderzoek is geconcludeerd dat het plaatsen en gebruiken
van de VAP een veilige manier is om polychemotherapie toe te dienen. De enige
onafhankelijke risicofactor voor het ontstaan van late complicaties is de
toediening van polychemotherapie voorafgaand aan de VAP implantatie.
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In Hoofdstuk V worden 112 patiënten beschreven bij wie na de behandeling met
op cisplatine gebaseerde polychemotherapie chirurgisch resttumor uit het
retroperitoneum is verwijderd. De aandacht wordt gevestigd op het belang van het
verkrijgen van histologie van de resttumor om de uiteindelijke effectiviteit van de
behandeling te kunnen beoordelen. De resttumor kan necrose en/of fibrose,
matuur teratoom of vitaal tumorweefsel bevatten. Resectie van necrose of fibrose
is eigenlijk niet nodig en heeft ook geen therapeutische consequenties. Resectie
van matuur teratoom is wel zinvol omdat het de groei van deze in potentie
maligne cellen voorkomt. Indien er nog vitaal tumorweefsel wordt gevonden,
dient de chemotherapeutische behandeling te worden voortgezet. De histologie
van de resttumor en de chirurgische morbiditeit van de ingreep zijn bestudeerd.
Daarnaast is gezocht naar mogelijke factoren die het ontstaan van complicaties
kunnen verklaren. De mediane grootte van de verwijderde resttumor was vier cm,
met een spreiding van 0-18 cm. Bij tien patiënten (9,0%) bevatte de resttumor
nog vitaal tumorweefsel. Bij 49 patiënten (44,1%) werd alleen necrose en/of
fibrose gevonden en bij 49 andere patiënten (44,1%) bevatte de resttumor matuur
teratoom. Bij drie patiënten (2,8%) werd geen resttumor gevonden tijdens de
laparotomie. Er zijn 26 complicaties bij 20 patiënten opgetreden (18,0%). De
meest voorkomende complicatie was een urineweginfectie, dit trad bij negen
patiënten op (8,1%). Er is een patiënt overleden tijdens de inductie van de
anesthesie. Obductie heeft bij deze patiënt geen duidelijke verklaring opgeleverd
voor de doodsoorzaak. Er kon geen significante relatie worden aangetoond tussen
het optreden van een complicatie en de leeftijd van de patiënt, de grootte van de
resttumor, de operatieduur, het ondergaan hebben van een eerdere laparotomie of
de histologische bevindingen. In de discussie worden de opgetreden complicaties
bij deze patiënten aan de hand van de beschikbare recente literatuur vergeleken
met de beschreven complicaties door auteurs uit andere klinieken, en er wordt
aandacht besteed aan technieken om de histologie van de resttumor te
voorspellen. Uit dit onderzoek is geconcludeerd dat de chirurgische verwijdering
van resttumor nog steeds moet worden gezien als de gouden standaard voor de
beoordeling van de effectiviteit van polychemotherapeutische behandeling. Het is
een relatief veilige chirurgische procedure met een morbiditeit van 18,0%, die
vooral bestaat uit urineweginfecties (8,1%). Kennis van de potentiële complicaties
die bij deze ingrepen kunnen ontstaan, zou het optreden hiervan kunnen beperken.
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In Hoofdstuk VI wordt beschreven dat na succesvolle behandeling met
polychemotherapie er niet alleen resttumor kan achterblijven in het
retroperitoneum, maar ook in de longen. Er wordt aandacht besteedt aan het feit
dat de indicatie voor thoracotomie bij patiënten met NSTT heel anders is dan bij
andere gedissemineerde maligniteiten. In het algemeen is chirurgie bij deze laatste
groep namelijk de enige curatieve optie, terwijl bij patiënten met NSTT de
indicatie voor thoracotomie eerder een controle op de effectiviteit van
chemotherapie is, of het voorkomen van een ’growing teratoma’. In het
Academisch Ziekenhuis Groningen was de beslissing om een thoracotomie te
verrichten mede afhankelijk van de histologie van de resttumor in het
retroperitoneum. De verwachting was namelijk dat de resttumor in de longen
dezelfde componenten zou bevatten als de retroperitoneale resttumor. Indien de
resttumor uit het retroperitoneum alleen necrose of fibrose liet zien, werd er in het
algemeen geen thoracotomie uitgevoerd. Als de retroperitoneale resttumor matuur
teratoom bevatte, werd een thoracotomie verricht om een ’growing teratoma’ te
voorkomen. Als er in het retroperitoneum vitaal tumorweefsel was gevonden
kreeg de patiënt eerst tweedelijns polychemotherapie. De resultaten en
complicaties van resectie van resttumor uit de longen bij 31 patiënten met
stadium IV NSTT zijn onderzocht, daarnaast is de overleving van deze patiënten
berekend. De verkregen histologie van de pulmonale resttumor is vergeleken met
de retroperitoneale resttumor, als bij dezelfde patiënt voorafgaand aan de
thoracotomie een laparotomie was uitgevoerd. In de periode van 1979 tot 1996
zijn er 32 thoracotomieën uitgevoerd bij 31 patiënten. Bij negen thoracotomieën
werd er een solitaire metastase verwijderd (28,2%) en bij 23 thoracotomieën
(71,8%) multipele metastasen. De mediane grootte was 15 mm, met een spreiding
van 2-60 mm. Er zijn vijf peroperatieve complicaties opgetreden bij vier patiënten
(12,5%), bestaande uit respectievelijk: twee maal minimale luchtlekkage, twee
maal een accidentele arteriële bloeding en eenmaal slijmretentie, waardoor de
beademing werd bemoeilijkt. Er deden zich drie ernstige postoperatieve
complicaties voor (9,4%): een patiënt moest gedurende vijf dagen nabeademd
worden, bij een andere patiënt trad een pneumothorax op waarvoor drainage
noodzakelijk was en de derde patiënt ontwikkelde een pneumonie enkele dagen na
de ingreep. Daarnaast zijn er 11 minder ernstige postoperatieve complicaties
opgetreden (34,4%), die niet hebben geleid tot een verlenging van de
ziekenhuisopname van langer dan twee dagen. Histologisch onderzoek van de
resttumor liet bij 16 patiënten matuur teratoom zien (51,6%), bij 11 patiënten
alleen necrose en/of fibrose (35,5%) en bij vier patiënten vitaal tumorweefsel
(12,9%). Bij 20 van de 31 patiënten was er voorafgaand aan de
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thoracotomie ook een laparotomie verricht waarbij resectie van resttumor uit het
retroperitoneum plaatsvond. Bij 10 van deze 20 patiënten (50,0%) kwam de
histologie van de verwijderde resttumor uit retroperitoneum en longen niet
overeen. Gedurende een mediane follow-up van zeven (spreiding 0,2-16,9) jaar,
overleden er vijf patiënten aan de gevolgen van hun ziekte. De vijfjaars
overleving is 86,8% en de tienjaars overleving is 82,2%. Geconcludeerd wordt dat
alle resttumor na behandeling met chemotherapie bij patiënten met NSTT
chirurgisch verwijderd dient te worden, onafhankelijk van de histologie van eerder
verwijderde lesies. Met dit beleid kan, met een minimale morbiditeit, een tienjaars




Na het behalen van mijn artsenbul in december 1993 werd bekend dat ik vijf
maanden later in het Academisch Ziekenhuis Groningen kon komen werken als
AGNIO (assistent-geneeskundige-niet-in-opleiding) Chirurgie. Om deze wachttijd
te overbruggen ben ik bij de Chirurgische Oncologie begonnen met het onderzoek
dat heeft geleid tot dit proefschrift. Hoewel ik deze wachttijd destijds erg lang
vond, ben ik achteraf blij dat ik de tijd heb gehad om een aantal zaken goed op
de rails te zetten. Later bleek namelijk maar al te duidelijk, dat het doen van
onderzoek naast een volledige baan als AGNIO en later als AGNIO/docent niet
altijd meevalt. Op de momenten dat de stress en de frustraties hoog opliepen heb
ik vaak tegen mezelf gezegd dat het ook wel een ontzettend stom idee was om
onderzoek te doen in je vrije tijd en dan ook nog te willen promoveren. Gelukkig
hebben de afgelopen drie jaar de positieve periodes de boventoon gevoerd. Het
houden van voordrachten op nationale en internationale congressen en de
acceptatie van mijn manuscripten in vooraanstaande tijdschriften maakten dat ik
af en toe oprecht trots was op de behaalde resultaten. Ook prees ik mezelf vaak
gelukkig met zoveel mensen om me heen die mij op allerlei manieren hebben
geholpen:
Allereerst wil ik mijn promotores Prof. Dr. H. Schraffordt Koops en Prof. Dr.
D.Th. Sleijfer en mijn co-promotor Dr. H.J. Hoekstra bedanken. Mijn collega’s
hielden vaak klaagzangen over hun respectievelijke begeleiders omdat het altijd
zo lang duurde voordat ze hun manuscripten terug kregen. Van mijn drie
wetenschappers kreeg ik de manuscripten echter altijd binnen twee dagen, zoniet
dezelfde dag nog, gecorrigeerd en wel terug. Dat heb ik steeds enorm
gewaardeerd, omdat ik weet hoeveel tijd en energie dit kost. Professor Schraffordt
Koops dank ik in het bijzonder voor het in mij gestelde vertrouwen, voor de
immateriële en materiële steun die ik tijdens het onderzoek heb gekregen, voor de
vele aan mij gewijde uren en voor de zorgvuldig door hem bijgehouden
patiëntenregistratie. Professor Dirk Sleijfer wil ik graag bedanken voor zijn grote
inzicht, voor zijn gestructureerde werkwijze, opbouwende kritiek en voor alles (!)
wat ik van hem geleerd heb, maar ook voor de bemoedigende woorden die af en
toe nodig waren. Doctor Harald Hoekstra bedank ik vooral voor zijn roemruchte
directe benaderingswijze, het ongeëvenaarde vermogen om vaart in de wetenschap
te houden en voor de vele waardevolle adviezen.
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De leden van de beoordelingscommissie, Prof. Dr. H.J.A. Mensink, Prof. Dr.
J. Oldhoff en Prof. Dr. Th. Wobbes, bedank ik hartelijk voor hun bereidheid om
dit proefschrift te beoordelen.
Hiernaast zijn er verschillende personen die ik speciaal wil noemen, omdat zij
zich op verschillende fronten hebben ingezet voor de in dit proefschrift
beschreven onderzoeken.
In de eerste plaats is dit Jos Droste, die voor alle onderzoeken de statistiek heeft
verzorgd. Door zijn hulp en inzicht is de kwaliteit van de manuscripten enorm
gestegen. Ook Jos heeft het meeste van dit werk naast zijn normale baan verricht,
waarvoor ik hem heel hartelijk wil bedanken. Dr. Jan Marrink en Petra Visser
hebben een groot aandeel gehad in het artikel over de tumormerkstof TRA-1-60.
Jan Marrink bedank ik voor de prettige samenwerking en voor het bieden van de
mogelijkheden om dit onderzoek te kunnen uitvoeren. Petra heeft alle (honderden)
bepalingen verricht in de onderzoeks- en de controlegroep: heel hartelijk bedankt
hiervoor! Twee studenten, Nicole Lemmers en Arjen Nijboer hebben elk
afzonderlijk hard gewerkt aan de onderzoeken over respectievelijk de VAPs en de
resecties van resttumoren. Beide wens ik veel succes in de toekomst toe! Cees
Koppe bedank ik voor al haar hulp als secretaresse. Vooral in het begin, bij het
ontcijferen van de handschriften van Schraffordt Koops en Hoekstra heb ik deze
hard nodig gehad. Dhr. J. Bosker, zonder twijfel de vriendelijkste man op het
AZG-terrein, heeft keer op keer alle statussen aangevraagd, opgezocht, bewaard
en zo nodig achtergehouden. Mw. Judith Abma heeft op voortreffelijke wijze de
Engelse teksten gecorrigeerd of uit het Nederlands vertaald. Prof. Dr. W.M.
Molenaar, Dr. H.W.A. de Bruijn, Dr. N.J.M. Freling, Dr. J.Th. Plukker, Dr.
W.T.A. van der Graaf, Dr. Z.J. de Langen, Prof. Dr. T. Ebels en P.W. Andrews,
MD, PhD, bedank ik voor hun waardevolle bijdragen als medeauteurs.
Nu ik mijn opleiding tot algemeen chirurg zal volgen in de regio Nijmegen wil ik
op deze plaats ook graag Prof. Dr. R. van Schilfgaarde, hoofd van de afdeling
Chirurgie, alle (vaste en tijdelijke) stafleden Heelkunde, het personeel van de
Centrale Spoedopvang, alle verpleegkundigen en mijn collega assistenten in
Groningen bedanken voor de plezierige tijd die ik op de afdeling gehad heb.
Vooral de tijd die we met de assistentengroep hebben gewerkt aan het cabaret
voor de chirurgendagen was onvergetelijk!
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Hoogst waarschijnlijk zal ik heimwee krijgen naar mijn driemaandelijkse
onderwijsperiodes. Ik heb altijd met veel plezier onderwijs gegeven aan de
studenten in de Introductiecursus en ook de ’onderwijsgroep’ van de afdeling
Chirurgie zal ik missen. De enthousiaste inzet van deze groep mensen voor het
onderwijs aan studenten en co-assistenten moet binnen de faculteit der Medische
Wetenschappen als een voorbeeld gezien worden. Met name noem ik hierbij Prof.
Dr. Rein Zwierstra en Ruud Venekamp van wie ik onder andere
presentatievaardigheden en verschillende onderwijsmethoden heb geleerd. Beide
hebben een talent voor het geven van onderwijs met daarnaast een soort vrolijke
deskundigheid die moeilijk is uit te leggen. Bovendien hebben zij veel waardering
voor mij getoond en ik ben er zeker van dat ik alles wat ik van hen geleerd heb
in de toekomst nog vaak goed kan gebruiken! Marjo Keijer, Atie van Onselen en
Marjan van der Kolk bedank ik voor alle steun en de gezelligheid op ’onze’
kamer.
Dan zijn er nog enkele personen die er, elk op hun eigen manier, aan hebben
bijgedragen dat ik met dit promotie onderzoek begonnen ben. Wim de Graaff, die
zelf promoveerde in 1992, heeft mij enthousiast gemaakt voor de (ik citeer)
’wonderlijke wereld van de kiemceltumoren van de testis’ (teratoma betekent
wondergezwel). Hij introduceerde mij bij de Chirurgische Oncologie.
Samen met Willem Terpstra heb ik in mijn studententijd langdurig onderzoek
gedaan bij de toenmalige vakgroep Fysiologie. In die periode heeft Dr. Jaap
Muntinga ons laten zien dat het doen van onderzoek heel leuk kan zijn, en dat het
belangrijk is om nieuwsgierig te blijven. Ik ben er nog steeds van overtuigd dat
het niet toevallig is dat zowel Willem als ik ervoor gekozen hebben om door te
gaan met het doen van onderzoek.
Jean Paul van Basten heeft in nagenoeg dezelfde periode als ik bij de chirurgische
oncologie onderzoek gedaan naar de gevolgen van het hebben van een
kwaadaardige testistumor. Een onderzoekslijn die parallel loopt, maar natuurlijk
ook veel raakvlakken heeft met de in dit proefschrift beschreven onderwerpen. Ik
ben zeer vereerd dat mijn twee ’wetenschapsmaatjes’ Jean Paul en Willem bereid
zijn mij als paranimfen tijdens de promotie bij te staan.
Dit proefschrift is opgedragen aan mijn ouders, Annie en Wim Gels. Zij hebben
ervoor gezorgd dat ik samen met mijn zus(je) Trudy en broer(tje) Hans een
onbezorgde jeugd heb gehad. Daarnaast hebben zij mij gestimuleerd en in de
gelegenheid gesteld om te studeren. Hen wil ik in het bijzonder bedanken voor
hun onvoorwaardelijke steun en voor het feit dat ik altijd op ze kan rekenen.
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Dankwoord
Ook mijn schoonouders, Riet en Ben Keemers, ben ik veel dank verschuldigd.
Naast de mentale steun die ik ontvang word ik ’schandalig’ verwend door deze
twee mensen die een jaar geleden officieel mijn tweede vader en moeder werden.
Het meest, tot besluit, bedank ik mijn levenspartner Peter Keemers.
Lieve Peter, je aanmoediging, ondersteuning, geduld, financiële deskundigheid en
liefde waren onmisbaar. Samen met onze je-weet-wel-kater Gijs heb je heel wat
Nederlandse en Engelse proefvoordrachten moeten aanhoren. Vooral mijn eerste
buitenlandse voordracht in Boston kende je uiteindelijk bijna woordelijk uit je
hoofd. Er zijn momenten geweest dat je meer in mij geloofde dan ikzelf, maar
tenslotte had jij gelijk (’Natuurlijk!’ zou je als rechtgeaard accountant zeggen).
Het is moeilijk in woorden uit te drukken hoeveel je voor mij betekent. In ieder
geval is je vermogen om een warme en solide thuisbasis te creëren mij heel




De schrijfster van dit proefschrift werd geboren op 24 juni 1967 te Wierden.
Zij bezocht het Pius X-College te Almelo en behaalde in 1985 haar VWO
diploma. Aansluitend studeerde zij Geneeskunde aan de Rijksuniversiteit
Groningen. Tijdens haar studie was zij actief als bestuurslid van de studenten
tennisvereniging ORIOL en in het studiejaar ’89/’90 was zij secretaris van het
dagelijks bestuur van de Overkoepelende Studenten Sport Organisatie ACLO
(Academische Centrale voor Lichamelijke Opvoeding). Haar wetenschappelijke
stage verrichtte zij bij de vakgroep Fysiologie. In de tweede fase was zij student-
assistent bij de vakgroep Gynaecologie & Obstetrie in het AZG. Zij doorliep haar
co-schappen in het Martiniziekenhuis te Groningen met als afsluiting een keuze
co-schap Heelkunde.
In december 1993 behaalde zij haar artsexamen en aansluitend begon zij met
onderzoek bij de Chirurgische Oncologie in het AZG. In juni 1994 verkreeg zij
een aanstelling als AGNIO (assistent geneeskundige niet in opleiding) bij de
vakgroep Chirurgie. Van maart 1995 tot maart 1997 werkte zij deels als AGNIO
Chirurgie en deels als universitair docent waarbij zij het vaardigheidsonderwijs
aan medisch studenten verzorgde. Daarnaast werkte zij aan de voltooiing van dit




behorende bij het proefschrift
Testicular Germ Cell Tumors. Developments in Surgery and Follow-up.
1. De ’wait-and-see policy’ bij patiënten met een klinisch stadium I non-
seminoma testistumor is een verantwoord beleid; hierbij is een follow-up
periode van vijf jaar na de orchidectomie voldoende. Dit proefschrift
2. Voor de vroege opsporing van eventuele longmetastasen in de follow-up
van patiënten met een klinisch stadium I non-seminoma testistumor kan
beter een CT-scan dan een röntgenfoto van de thorax worden gemaakt.
Dit proefschrift
3. De nieuwe tumormerkstof TRA-1-60 is veelbelovend in de vroege
diagnostiek van een recidief bij patiënten met een non-seminoma
testistumor en heeft een additionele waarde naast de bestaande
tumormerkstoffen AFP en hCG. Dit proefschrift
4. Na behandeling met polychemotherapie van patiënten met een
gedissemineerde non-seminoma testistumor dienen alle eventueel
aanwezige retroperitoneale en/of pulmonale resttumoren chirurgisch
verwijderd te worden, onafhankelijk van de histologie van eerder
verwijderde lesies. Dit proefschrift
5. De ervaring van het team dat zich bezighoudt met de behandeling van
patiënten met maligne kiemceltumoren van de testis, is een belangrijke
prognostische factor voor de overleving.
6. Ruim 10% van alle patiënten met een zwelling in het hoofd-hals gebied
die wordt verwezen naar een perifeer ziekenhuis heeft een maligniteit,
ongeacht of deze zwelling initieel als verdacht is aangemerkt.
Niet gepubliceerd
7. Het is op zijn minst merkwaardig dat de universiteit de enige sector in het
onderwijs is waar van docenten geen bewijs van didactische bekwaamheid
wordt verlangd.
8. Het hebben van een goede gezondheid is niet zonder meer een gegeven
goed. De verantwoordelijkheid hiervoor zou in het algemeen beter
gedragen kunnen worden.
9. Wanneer vrouwelijke artsen naast een carrière als specialist ook een
gezinsleven nastreven getuigt dit niet van een gebrek aan ambitie, maar
juist van veel ambitie.
10. Wat het leven ook de moeite waard maakt, zonder vriendschap stelt het
niets voor. Epicurus 341-270 v.C.
11. Wanneer iemand van plan is een motor(fiets) te kopen, zou hij of zij
verplicht moeten worden voorafgaand aan deze koop een week lang mee
te lopen op de spoedopvang van een traumacentrum.
12. De schoonheid van een aquarel is omgekeerd evenredig aan de afstand
waarop het bekeken wordt.
13. Alle overkoepelende studenten sport organisaties in Nederland dienen
een voorbeeld te nemen aan de ACLO (Academische Centrale voor
Lichamelijke Opvoeding) in Groningen.
14. Een huwelijk wordt niet gesloten, maar geopend.
Mariël Gels Groningen, 28 mei 1997.
